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Abnormal glycosylation is a universal feature of cancer; however, in the past these 
changes have been viewed as passive by products of abnormal metabolism with efforts 
largely being directed at using these characteristic abnormalities as biomarkers for cancer 
detection. More recently glycosylation has been shown to play a number of crucial roles 
in the activity and localization of proteins and in the overall behavior of cells. While 
cancer related glycosylation abnormalities may have a metabolic origin, they likely play a 
much larger role in the maturation of the disease phenotype and in its eventual 
progression. In order to study changes in glycosylation, alterations in the glycan patterns 
need to be made this can either be done by genetic manipulation of the glycosylation 
machinery or by altering fluxes through the pathway via metabolic oligosaccharide 
engineering. One of the major advantages of using a flux based approach is that it can 
make use of pharmacologically relevant small molecules that are easier to use than 
genetic means. However a significant roadblock to use to metabolic oligosaccharide 
engineering is the low uptake efficiency of sugar molecules, this is overcome by the use 
of short chain acid (SCFA) linked sugar molecules. The addition of these SCFA groups 
converts these molecules into a unique form of prodrug in that they need to resist esterase 
processing outside the cell and require intracellular esterase processing to release the core 
sugar. The first part of this thesis characterizes the esterase processing of these sugar 
analog prodrugs. The analogs were found to be fairly resistant to extracellular 
inactivation surviving for between 2 and 4 h in 100% fetal bovine serum. In comparison 
intracellular processing was shown to be much faster, interestingly there appeared to be 
an activation of the intracellular esterases by analog treatments. Investigation of this 
 
iii 
crosstalk revealed that increased sialylation of carboxyl esterases led to a stabilization of 
more active trimeric and hexameric forms of this enzyme. The next portion of the study 
used metabolic oligosaccharide engineering as a tool to alter glycosylation and the 
epidermal growth factor receptor’s sialylation is observed to increase. The effect of 
increased sialylation on the epidermal growth factor receptor (EGFR) is investigated and 
shown to lead to an inhibition of EGFR signaling. This understanding of the functional 
significance of altered glycosylation is then translated towards clinical end points with 
1,3,4-O-Bu3ManNAc shown to have remarkable synergy when used in conjunction with 
EGFR targeting drugs Erlotinib and Gefitinib. Finally, the underlying molecular 
mechanism by which this analog induced change in glycosylation affects receptor 
signaling is characterized. Increased sialylation caused by analog treatment was found to 
disrupt the galectin lattice which led to an increase in non clathrin mediated endocytosis 
wherein the resulting endosomes are fated primarily for degradation, this leads to a 
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INTRODUCTION TO THE THESIS 
 
1.1 OUTLINE OF THE THESIS 
Chapter 2 will familiarize the reader with some of the important concepts and 
ideas related to the research presented in later chapters. The chapter is divided into three 
main sections. The first gives a brief introduction to the field of metabolic engineering. 
The second section provides some background information on the field of metabolic 
oligosaccharide engineering. The third section looks at the process and importance of N-
glycosylation. 
The thesis is split up into three specific aims. In Aim 1, a MOE based small 
molecule approach to alter glycosylation is developed and characterized, the extracellular 
and intracellular processing in particular were assayed and characterized.   
Aim 2 then applies this approach to alter glycosylation in SW1990 pancreatic 
cancer cells and specific proteins whose glycosylation profiles are being affected are 
identified, this aim then explores the functional effect of alterations of glycosylation on 
the behavior of the epidermal growth factor receptor (identified in Aim1) and then 
focuses on developing novel therapeutic approaches for pancreatic cancer using 
complementary EGFR targeting drugs in combination. Finally non-natural sugar analogs 




In Aim 3, the molecular mechanism by which analog induced changes in 
glycosylation affect EGFR signaling is explored and characterized using computational 
and experimental approaches. 
 
1.2 SPECIFIC AIMS OF THE THESIS 
Specific Aim 1: Was to develop and evaluate metabolic flux-based tools to 
manipulate glycosylation focusing on the extracellular and intracellular processing 
of these sugar analog prodrugs.  
Aim 1 is divided into two specific sub aims: 
a. Characterization of the extracellular processing and inactivation of short chain 
fatty acid (SCFA) linked sugar analogs. 
b. Elucidation of the intracellular processing of the SCFA-linked sugar analogs by 
esterases and their effect on the availability of the core sugar within the cell for 
metabolic flux modulation. 
This aim focuses on the characterization of both extracellular and intracellular 
processing of short chain fatty acid linked sugar analogs in order to determine their 
viability as small molecule glycosylation effectors. This aim further explores the 
intriguing crosstalk between SCFA linked sugar analogs and the intracellular esterases 
that process them. 
 
In order to effectively use MOE sugar analogs as ‘pseudo pro drugs’ a thorough 




serum esterases is needed.  The results for Specific aim 1.a. are given in Chapter 3 
wherein SW1990 cells are used as a reporter cell line and short chain fatty acid linked 
sugar inactivation is characterized in 10%, 25% and 100% fetal bovine serum. 
After entry into a cell these sugar analog pro drugs need to be processed by intracellular 
esterases to yield the core sugar that can then intercept the glycosylation machinery and 
cause alterations in the glycosylation profile of the cell. Chapter 4 is focused on specific 
aim 1.b. and elucidates the intracellular processing of these sugar analogs, the chapter 
further explores the intriguing crosstalk and feed forward activation of these intracellular 
esterases observed on analog treatment.  
 
Specific Aim 2: Applied these flux based tools to identify surface receptors 
susceptible to changes in glycosylation in cancer cells, determine the effect of altered 
glycosylation on receptor function and apply this toward new therapeutic strategies 
for pancreatic cancer 
Aim 2 consists of four specific sub aims: 
a. Glycoproteomics analysis of proteins from cancer cells subject to metabolic 
oligosaccharide engineering 
b. Surface receptors altered by MOE were functionally characterized using western 
blotting to (i) probe alterations in response/phosphorylation to the receptor’s 





c. Interactions between the sugar analogs and orthogonal therapeutic strategies such 
as drugs that target the same receptor but act by an alternative mode of action 
were characterized and chemically modified sugar analogs were screened for 
similar effects.  
This aim will test the hypothesis that metabolic flux through glycosylation pathways plays 
an important role in determining the glycosylation profile of a cell and that 
glycosyltransferases are not the only determinant of observed patterns of glycosylation. It 
will also test the hypothesis that certain surface receptors are more susceptible to 
alterations in glycosylation profile and will be selectively affected when using sugar 
analogs to alter flux through glycosylation pathways. This aim will then test the 
hypothesis that changes in a cell surface receptor’s glycosylation profile correspond to 
changes in its signaling. This aim will further test the hypothesis that MOE based 
therapies can be used to augment existing orthogonal therapeutic strategies and that 
non-natural functionalized sugar analogs can elicit similar effects as their natural 
counterparts 
Specific aim 2 is addressed in Chapter 5 which describes the use of glycoproteomic 
mass spectrometry in SW1990 pancreatic cancer cells to identify proteins whose 
glycosylation profiles are changed in response to treatment with 1,3,4-O-Bu3ManNAc. 
characterization of the functional effect of increased sialylation of the epidermal growth 
factor receptor (identified in Aim 1.c as having increased sialylation on 1,3,4-O-
Bu3ManNAc treatment) and the development of a combinatorial approach wherein the 




(Erlotinib and Gefitinib). The azido derivative of this sugar analog (1,3,4-O-
Bu3ManNAz) is also shown to exhibit this synergistic interaction with Erlotinib. 
 
Specific Aim 3: To characterize the molecular mechanisms by which changes in 
glycosylation leads to altered receptor signaling, using EGFR as a model system: 
Aim 3 can be divided into two specific sub aims: 
a) A computational model of EGFR trafficking and recycling was implemented and 
used to predict possible molecular mechanisms for experimental observations 
from specific aim 2 b. 
b) Model predictions that internalization and recycling were key factors in the 
mechanism by which analog induced increases in EGFR sialylation affect its 
signaling were experimentally verified. 
c) Further characterization of internalization patterns showed a shift from clathrin 
coated endocytosis toward non clathrin coated endotcytosis consistent with 
modelling results 
This aim will attempt to identify the specific molecular mechanism by which analog 
induced changes in glycosylation affect receptor function. 
Specific Aim 3 is the focus of Chapter 6. Here a mathematical model is implemented 
and used to predict potential mechanisms by which increased sialylation could suppress 




critical factors experiments were performed that showed that the effect of the sugar 
analog was likely via a shift from clathrin coated endocytosis toward non clathrin coated 
endocytosis mediated by a disruption in the galectin lattice caused by increased 



















THE ROLE OF GLYCOSYLATION AND EMERGING 
METABOLIC OLIGOSACCHARIDE ENGINEERING IN 
CANCER PROGRESSION AND THERAPIES 
 
ABSTRACT 
This introductory chapter covers three topics that are fundamental to the subsequent work 
described in this thesis.  First, in Section 2.1, an overview of an often underappreciated 
driving force behind cancer progression – which is the role of glycosylation – is covered. 
Then, in Section 2.2, N-glycans – which is a subset of glycosylation that virtually all cell 
surface and secreted glycans are subject to – are discussed.  Finally, in Section 2.3 
“metabolic oligosaccharide engineering” is covered; this emerging technology is the basis 
of the cancer therapies described in the remainder of this thesis including (1) the 
metabolic processing of prodrug sugar analogs (in Specific Aim 1/Chapters 3 and 4), (2) 
the understanding of the functional role analog induced changes in glycosylation play in 
EGFR signaling (in Specific Aim 2/Chapter 5); and the underlying molecular mechanism 







2.1 GLYCOSYLATION IN THE CONTEXT OF CANCER 
2.1.1 The Importance of Glycosylation 
The post translational modifications of proteins is crucial in developing the complex 
functions involved in human health and disease, of these modifications glycosylation is 
one of the most complex and ubiquitous (1, 2). Numerous enzymes and transporters work 
in concert to attach a plethora of oligosaccharide structures to proteins and lipids. 
Glycosylation has been shown to play a number of important roles in the functioning of 
proteins and lipids. The ‘Yin-Yang’ relationship between O-GlcNAcylation 
phosphorylation of cytoplasmic and nuclear proteins plays a role in dynamic signaling 
processes (3, 4). The proper folding and thus effective functioning of nascent proteins has 
been shown to be dependent on the attachment of N-linked oligosaccharides (5). The 
surface of a cell is decorated with a vast variety of glycans that help modulate numerous 
essential cell recognition and binding events (1, 6). Glycans on the cell surface not only 
determine how a cell is perceived and how it perceives its environment but also makes up 
a storage system for a wealth of information (7). This ‘carbohydrate code’ plays an 
important role in human health and disease whereby alterations in the glycan display can 
help to direct and mediate the immune system (6, 8, 9). Considering the vast repertoire of 
functions glycosylation is associated with it is not surprising that abnormalities and 
anomalies are correlated to diseases such as cancer (10), congenital diseases (11) and 
immune dysfunction (12). 
Despite the importance and prevalence of glycosylation attempts to decipher the 
molecular mechanisms behind their functions has lagged behind studies on protein and 




glycan structures but also due to the innate heterogeneity caused by the non template 
driven nature of the glycosylation biosynthetic process (1). While homogenous glycans 
can be produced by chemical (14) or enzymatic (15) methods cellular studies necessitate 
a means to modulate these glycans in their natural environment. It is from this need that 
the field of metabolic oligosaccharide engineering (MOE) was born (1). 
2.1.2 Abnormal Glycosylation is a Hallmark of Cancer (16, 17, 90, 91).  
Glycosyltransferases such as MGAT5 have been implicated as key factors in generating 
the characteristic alterations in glycosylation observed in cancer (17, 91). However, 
glycosylation is a non-template driven process and as a result, apart from the availability 
of the necessary enzymes the flux of substrate through the pathways could also influence 
the types of structures being produced. In fact, the Warburg effect (which has recently 
been recognized as ‘next generation’ hallmark of cancer (18, 92)) wherein cells take up 
large amounts of glucose to allow the cell to use glycolysis as a primary mode of energy 
production could lead to significant changes in metabolic flux through the glycosylation 
machinery as a small fraction of glucose taken up is shunted into the hexose biosynthetic 
pathway. Hence, it too could play a role in generating the characteristic glycosylation 
patterns observed in cancer. While a number of studies target the glycosyltransferases as 
a means of studying changes in glycosylation (19, 93), MOE provides an alternative 
means of modulating glycosylation patterns and since it starts out using the cells existing 
glycosylation machinery it could prove a useful tool for identifying proteins that are 
susceptible to alteration in glycosylation as well as what changes in glycosylation 




2.1.3 Understanding the Functional Role of Abnormal Glycosylation in Cancer 
Progression 
For the most part the changes in glycosylation pattern have been viewed as passive by 
products of abnormal metabolism with efforts largely being directed at using these 
characteristic abnormalities as biomarkers for cancer detection (20, 21, 94, 95). More 
recently glycosylation has been shown to play a number of crucial roles in the activity 
and localization of proteins and in the overall behavior of cells (19, 22-26, 93, 96-100). 
For example α2-6 sialylation has been shown to modulate carcinoma diffentiation in vivo 
(19, 93) and the N-linked glycosylation of IL-13 Rα2 has been shown to be essential of 
IL-13 activity
 
(26, 100). While cancer related glycosylation abnormalities may have a 
metabolic origin they likely play a much larger role in the maturation of the disease 
phenotype and in its eventual progression. With cell surface receptor known to be 
universally glycosylated, understanding the effect of alterations in the glycans attached to 
them on their behavior is essential for a more complete understanding of the disease. 
Altered glycosylation could play a role in altering the sensitivity of cancer cells to 
environmental cues and may color how cancer cells perceive their environment. In 
addition, many surface receptors are linked to numerous phosphorylation cascades and 
altered behavior of these proteins could be amplified downstream and could lead to 
alteration in gene expression in their own right which could play a role in the progression 
of the disease. In addition to this glycosylation forms a large portion of the external 
interface by which cells interact with their environment, as a result alterations in 
glycosylation affect not only how a cell perceives its environment but also how it is 




by which altered glycosylation can affect receptor function will not only improve our 
understanding of the role glycosylation play in the progress of cancer but could also 
suggest possible orthogonal therapeutics that could synergistically be combined with 
glycosylation based therapy. 
2.1.4 Applying Glycosylation Based Therapies Towards Pancreatic Cancer. 
Pancreatic cancer which has one of the worst prognoses of any type of cancer with 5 year 
survival rates of as low as 4% (27, 101). As a result there is a pressing need for new 
therapeutic strategies. One approach that is being explored is to target EGFR, as the 
overexpression of EGFR in pancreatic cancer has been linked to poor prognosis (28-30, 
102-104). Gefitinib and erlotinib are two such EGFR antagonists that block ATP binding 
to EGFR tyrosine kinase and thus reduce signaling down the EGFR signaling cascade 
and hence inhibiting cancer cell proliferation and survival (31-33, 105-107). Since altered 
glycosylation induced by analog treatment likely acts by an orthogonal mechanism there 
is a possibility that they will have synergistic interactions with these drugs. Metabolic 
Oligosaccharide Engineering has been shown to be an effective method of installing 
novel functional groups on the surface of cells (34, 35, 108, 109). In addition since 
increased sialylation is one of the alterations commonly observed in cancer, with cancer 
cells often possessing elevated levels of sialyltransferases (19, 36, 37, 93, 110, 111). As a 
result increased sialylation has been used as a means of identifying tumors by MRI (38, 
112) and Ac4ManNAz has been shown to preferentially label tumor tissue over healthy 
tissue (39, 113). Hence, the development of an effective therapeutic delivery system 




means of better directing therapeutics towards cancer cells and help avoid some of the 
side effects of chemotherapy caused by non-specific activity of the drugs used. 
This study aims to improve our understanding of some of the functional roles 
glycosylation plays and to translate this information towards clinical end points. It will 
also provide a procedural template by which the effect of altered glycosylation on protein 
and cell behavior can be effectively studied in the context of different types of cancer as 
well as in other diseases.  
 
2.2 N-LINKED GLYCOSYLATION 
2.2.1 A General Introduction to N-linked Glycosylation 
N-linked glycosylation is the covalent linking of a carbohydrate to a protein via an 
asparagine residue in the consensus sequence Asn-X-Ser/Thr where X can be any amino 
acid except proline (40-42). Glycan size, complexity, composition and structure varies 
between glycans at different glycosites on a protein, between glycoproteins and between 
cell types, tissues and species (43, 44). N-Linked glycans are typically large, hydrophilic 
structures with molecular weights that range from around 1800 to 2800 KDa (45). The 
size and complexity of glycans sets them apart from other common post translational 
modifications which tend to be limited to involve a few molecules at most, whereas the 
size of glycans by volume can rival the size of the protein itself. As a result the addition 





2.2.2 N-Linked Glycan Synthesis and Processing 
Although the final glycan structure displayed on a protein has been shown to be highly 
heterogeneous the initial ‘core glycan’ that is attached to nascent polypeptides inside the 
endoplasmic reticulum (ER) is quite homogenous (GlcNAc2Man9Glc3) as depicted in 
figure 2.1 (5, 46).  
The first step in N-glycosylation is the attachment of this core glycan to membrane bound 
dolichylpyrophosphate precursor molecule on the cytoplasmic side of the ER (40, 44, 
47). The enzyme flippase then ‘flips’ the glycan onto the inside of the ER. Enzymes 
within the ER then transfer the glycan from the dolichylpyrophosphate molecule onto the 
asparagine residue in the consensus sequence in the growing polypeptide (48-50). The 
‘sugar tree’ is then ‘trimmed’ within the ERby mannosidases and glucosidases (44, 51). 
Finally the glycoproteins are transferred to the Golgi apparatus where further removal of 
mannose residues occurs. Often new sugar residues are also added within the golgi 
apparatas to produce complex glycan structures (5). A rough schematic representation of 
this process is shown in figure 2.2. While the biosynthetic processes in the ER are 
subject to significant quality control, the Golgi complexes do not have the same 
mechanisms in place and as a result mutations to glycosyltransferases and glucosidases 
can lead to abnormal glycans being attached to glycoproteins within the Golgi (52, 53). 
The absence of enzymes at the ER stage of the pathway leads to proteins that lack the 
oligosaccharide entirely, whereas absent enzymes in the Golgi can lead to alterations 
branching patterns and abnormal fucosylation. Numerous congenital disorders of 
glycosylation have been identified and shown to be due to the lack of certain enzymes or 




2.2.3 The Roles of N-Glycosylation 
One of the most important and well characterized roles played by N-linked glycosylation 
is in the regulation of folding of newly synthesized polypeptides (43, 55). The necessity 
for glycan attachment can vary from protein to protein and also be glycosite dependent 
within the same protein with glycans presenting both ‘global’ and ‘local’ effects (5). The 
effects on folding can be direct or indirect. Direct effects on folding include: interacting 
with nearby  residues and helping organize them into secondary structures (56, 57), large 
polar oligosaccharides can serve to orient sections of the peptide toward the solvent 
facing surface of the protein (46, 58), these glycans can also play a role in the refolding 
of proteins in a role similar to the one played by molecular chaperones (59). Although 
these glycans are not typically essential in maintaining the conformation of these proteins 
after the protein has been properly folded they have been shown to continue to have 
minor stabilizing effects (46, 55, 56).  
A good example of the indirect effects of N-glycosylation is observed in the ER with the 
calnexin-calreticulin cycle which is a unique chaperone system (60-62). Calnexin 
(membrane bound) and calreticulin are lectins (proteins that bind to glycans). These 
proteins bind to the newly formed glycan which serves as a means of entry into the cycle, 
the two lectins bind transiently to the glycan whilst a co-chaperone ERp57 ensures the 
synthesis of necessary disulphide bridges in the protein. The cycle serves to make folding 
process of the protein more deliberate and accurate (63-67).  
ER associated degradation (ERAD) is also modulated by N-glycosylation (68, 69), here 
the trimming of the nascent glycan by mannosidase aids the sorting process and ensures 




degradation (68, 70, 71).  The slow activity of the mannosidases is also believed to play 
an essential role in a timing mechanism wherein the lifetime of a protein is determined 
(55, 72, 73). 
Lectins like ERGIC-53 and VIP36 which are specific to mannose are thought to serve as 
cargo capture and transport receptors for transport of glycoproteins from ER-to-Golgi. 
ERGIC-53 helps to speed up in a glycan dependent manner Cathepsin Z transport from 
the ER to the Golgi (74). 
Lectins also work to sequester lysosomal hydrolases from the trans-golgi network. 
Lysosomal hydrolases in the cis-golgi compartment are specifically modified with the 
addition of a GlcNAc phosphate onto terminal or sub terminal mannose residues by 
enzymes localized to that compartment. The removal of these GlcNAc residues results in 
the presentation Mannose-6-Phosphate (M-6-P) groups. M-6-P is recognized by a series 
of receptors, this interaction plays a key role in transport of these hydrolases via clathrin 
coated vesicles to endosomes and lysosomes (75). 
 
2.3 METABOLIC OLIGOSACCHARIDE ENGINEERING 
2.3.1 Metabolic Engineering 
Metabolic engineering aims to alter cellular properties by modifying specific cellular 
pathways or introducing new ones. Typically metabolic engineering focuses on the 
importance of using metabolic fluxes as determinants of cellular physiology and as a 




than at individual components or reactions in isolation is a key concept of metabolic 
engineering. It aspires to shift focus away from individual enzymatic reactions and 
towards a more comprehensive integrated metabolic network (76).  
In order to quantitatively characterize and understand metabolic networks the concepts of 
metabolic fluxes were developed as a means by which reaction stoichiometry can be used 
to organize a mathematical framework upon which metabolic flux distributions can be 
structured (77). 
The first attempts to manipulate metabolic pathways were to improve productivity of 
microorganisms and started with the use of chemical mutagenesis and selective 
techniques. The field took a significant step forward with advent of molecular biology 
techniques that facilitated DNA recombination. The ability to make specific targeted 
changes to enzymes within a metabolic network led to the development of a number of 
metabolic engineering applications (78, 79). Metabolic engineering was used in microbes 
to improve their productivity and yield of native products (80-83). It enabled the 
expansion of substrate ranges in certain organisms and facilitated the production of 
metabolites that were either new to the host cell (84-86) or entirely novel (87, 88). 
Cellular properties were also engineered with cells imbued with the ability to tolerate 
hypoxic fermentation conditions (89), prevent overflow metabolism (90), etc. Finally 
another broad application of metabolic engineering has been in the study of entire organs 
or tissues and in the identification of targets for disease control (91). 
In order to explore and expand the landscape of protein structure and function, some 




analogs were tolerated and incorporated by the existing natural t-RNA synthetases (e.g. 
azidohomoalanine (92)) most required a corresponding mutation to its t-RNA synthetase 
(93-96). In contrast, incorporation of non-natural sugar analogs by metabolic 
oligosaccharide engineering was far easier and could be performed in almost any 
mammalian cell line without the need to tweak the biosynthetic machinery. Sialic acid 
engineering was especially attractive due to the observed permissivity of the sialic acid 
biosynthetic pathway (97-100). 
2.3.2 A Brief History of Metabolic Oligosaccharide Engineering 
Observation that changes in sialic acid metabolism promoted carcinogenesis in the early 
1980s led to attempts to inhibit sialic acid production (101). N-Acetyl-D-mannosamine 
(ManNAc) is the primary feedstock in the sialic acid pathway. The first passes at MOE 
focused on the use of fluoro analogs of ManNAc to inhibit the biosynthesis of sialic acid 
(102, 103). Numerous groups also attempted to develop mono and disaccharide analogs 
to inhibit glycosylation pathways as well as specific glycan motifs leading to the 
successful inhibition of sialyl lewis X (104, 105) and poly sialic acid structure production 
(106, 107). Like the discovery of penicillin, a series of unusual observations led to a 
ground breaking finding. These ManNAc analogs that had been designed to inhibit the 
sialic acid pathway were instead being converted into the corresponding non-natural 
forms of sialic acid and being installed into sialosides that were presented on the surface 
of the cell (102, 103). Reutter’s group expanded on these findings to show that ManNAc 
analogs with extended N-acyl groups could be used to deliberately engineer the cell 
surface (108, 109). This permissivity of the sialic acid biosynthetic pathway allowed a 




(97), azides (99) and ketones (98) to be incorporated onto the cell surface via the non-
natural forms of sialic acid. Figure 2.3 presents a summary of various MOE approaches. 
2.3.3 Developing and Characterizing SCFA-Linked Sugar Analogs as Tools for 
Metabolic Oligosaccharide Engineering (MOE). 
The uptake of naked sugar analogs is very inefficient and often requires millimolar 
concentration ranges for adequate uptake. To address this issue short chain fatty acid 
(SCFA) groups like the acetate group were attached to the analogs to make them more 
hydrophobic and hence facilitate their diffusion into the cell. These acetylated analogs 
were metabolized almost 900 fold more efficiently leading to more robust cellular 
responses in micro molar concentration ranges (104, 110). Attempts to further improve 
cellular uptake by increasing hydrophobicity using longer chain SCFAs like propionate 
and butyrate groups led to 1800 fold and 2100 fold higher flux through the sialic acid 
pathway respectively when compared to regular ManNAc (111).  
The SCFA-linked sugar analog acts somewhat like a prodrug in that it needs to be 
processed by esterases to yield the core sugar that can then influence the flux through 
glycosylation pathways. However, extracellular esterases present in serum could also 
process the analogs leading to inactivation of the analog. Therefore the extracellular 
processing of SCFA-linked sugar analogs needs to be properly characterized.   Secondly, 
once inside the cell the SCFA groups must be removed by intracellular esterases in order 
to release the core sugar. Thus the intracellular processing of esterases must also be 
studied, in addition to this intracellular esterases exist in the golgi apparatus and hence 




pathways and hence possible crosstalk between the sugar analogs and the esterases that 
are responsible for their processing must also be accounted for. 
2.3.4 New Layers of Complexity and Whole Molecule Effects 
For the most part it was assumed that these hybrid molecules were completely hydolysed 
and that resulting activity was because of the liberated core sugar or SCFA. One SCFA 
that was studied was n-butyrate. n-Butyrate is a known histone deacetylase inhibitor 
(HDACi) and therfore can inhibit the growth of cancer cells by up-regulating the 
production of cell cycle checkpoint p21 proteins. Similar to ManNAc, n-butyrate had 
poor pharmacological properties. However, when the two were combined the resulting 
compound had much better pharmacological properties than either on its own  the two 
acted as ‘mutual prodrugs’ (112).  
Bu4ManNAc depicted in figure 2.4 exhibited higher toxicity in cancer cells than a 
Bu5Mannose compound that had previously been evaluated as a means of delivery of n-
butyrate to cancer cells (111-113). Surprisingly, the two tributanoylated forms of 
ManNAc -1,3,4-O-Bu3ManNAc  and 3,4,6-O-Bu3ManNAc showed markedly different 
behavior. The 1,3,4-O-Bu3ManNAc showed a high flux through the sialic acid pathway 
with low toxicity whereas the 3,4,6-O-Bu3ManNAc showed very high toxicity (higher 
even than the Bu4ManNAc) (113). This indicated that apart from their direct effect, the 
two individual components also displayed some whole molecule effects that were unique 
to each compound. Both Bu4ManNAc and 3,4,6-O-Bu3ManNAc were shown to result in 




The discovery of whole molecule effects gave the understanding of extracellular and 
intracellular esterases that are involved in the processing of these sugar analogs a much 
greater importance. Apart from the complete hydrolysis of the compound that would 
render the SCFA-linked sugar analog unable to enter the cell at the much lower 
concentrations they are used at, the removal of a specific side group could fundamentally 
alter the activity of the analog (both qualitatively by selectively favoring certain patterns 
of SCFAs or quantitatively by changing the kinetics of butyrate removal). As a result the 
initial goal of this thesis was to characterize the extracellular esterase processing of these 
butyrated sugar analogs. 
Initial studies on intracellular esterases led to some unusual findings. An esterase activity 
assay designed to titrate a fluorescent esterase substrate against the SCFA analogs 
showed an increase in activity rather than a decrease without a corresponding change in 
transcription levels of various esterases measured by RT-PCR data. These results further 
implicate the importance of characterizing the crosstalk between esterases which are 
responsible for analog processing but are also N-glycosylated and hence could in turn be 














Figure 2.2: Outline of N-linked glycoprotein biosynthesis showing topography and major biosynthetic 
events.  Production of the Dol-PP-14-mer begins on the cytosolic side of the ER and is flipped to the 
luminal side after the assembly of two GlcNAc and five Man residues (A). An additional four Man and 
three Glc residues are added to create the GlcNAc2Man9Glc3 14-mer that is transferred en bloc by an 
oligosaccharyltransferase (OST) to a newly synthesized, yet unfolded peptide (B). Trimming of the Glc 
residues controls protein folding in the calnexin / calreticulin cycle in the ER (C). This is followed by 
transfer to the cis-Golgi lumen (D) where removal of four Man residues produces the GlcNAc2Man5 ‘core’ 
structure that is subsequently elaborated into a diverse array of high mannose, complex, and hybrid N-
glycans. Enzyme abbreviations are shown (where known), and updated information on enzymatic activity 
(indicated by the E.C. number) can be found in online data bases such as Kyoto Encyclopedia of Genes and 










Figure 2.3  Strategies for MOE involve the use of ManNAc, GalNAc, GlcNAc, Neu5Ac and fucose analogs. 
(A) Sialic acid engineering uses ManNAc or Neu5Ac analogs, these analogs allow the incorporation of 
functional groups (*) into cell surface or secreted glycol proteins. Functional groups on surface proteins 
can serve as (a) chemical handles for binding of labels or (b) modifying the interactions between cell 
surface moieties such as integrins. (B) GalNAc analogs can be incorporated into O-linked glycans as well 
as ECM polysaccharides. (C) fuc analogs can be used to study modification to fucosylated glycans which 






Figure 2.4 The SCFA ManNAc analogs have 3 main modes of activity. The complete hydrolysis of the 
compound results in n-butyrate groups (A) and the carbohydrate (the R1 modified ManNAc). Partial 
hydrolysis can result in the formation of a butanoylated analog lacking a butyrate group at either the C1-
OH or the C6-OH position. 3,4,6-O-Bu3ManNAc (C) has been shown to have high scaffold dependent anti-
cancer activity whereas 1,3,4-O-Bu3ManNAc (D) is shown to have a high flux through the sialic acid 
pathway and negligible toxicity. In general, the absence of a SCFA at the C6-OH position results in 
‘inactive’ analogs that have negligible toxicity, do not suppress oncogene activity and have a high flux 
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EXTRACELLULAR AND INTRACELLULAR 
PROCESSING OF SCFA-HEXOSAMINE ANALOGS; 
IMPLICATIONS FOR METABOLIC 
GLYCOENGINEERING AND DRUG DELIVERY 
ABSTRACT 
This chapter provides a synopsis of the esterase processing of short chain fatty acid 
(SCFA)-derivatized hexosamine analogs used in metabolic glycoengineering by 
demonstrating that that extracellular hydrolysis of these compounds is comparatively 
slow (e.g., with a t1/2 of ~ four hours to several days) in normal cell culture as well as in 
high serum concentrations intended to mimic in vivo conditions. Structure activity 
relationship (SAR) analysis of common sugar analogs revealed that O-acetylated and N-
azido ManNAc derivatives were more refractory against extracellular inactivation by 
FBS than their butanoylated counterparts consistent with in silico docking simulations of 
Ac4ManNAc and Bu4ManNAc to human carboxylesterase 1 (hCE1). By contrast, all 
analogs tested rapidly (i.e., within two hours) supported increased sialic acid production 
intracellularly thereby establishing that esterase processing once the analogs are taken up 
by cells not rate limiting.  
This chapter was originally published as Mathew, M. P., Tan, E., Shah, S., Bhattacharya, R., Meledeo, 
M. A., Huang, J., ... & Yarema, K. J. (2012). Extracellular and Intracellular Esterase Processing of 
SCFA–Hexosamine Analogs: Implications for Metabolic Glycoengineering and Drug 





Ester-containing small molecules are common in nature, exemplified by 
acetylsalicylic acid (aspirin), and they also proliferate as numerous prodrugs and 
profluorophores used medicinally, diagnostically, and for research purposes (1). The 
biological activity or therapeutic effects of these compounds depend intricately on the 
stability or lability of the ester group as well was the organ, tissue, or subcellular site of 
hydrolysis.  A group of these compounds with emerging significance, hexosamine 
analogs with ester-linked short chain fatty acid (SCFA) groups used in metabolic 
glycoengineering (illustrated by Ac4ManNAc and Bu4ManNAc, or their “R”-modified 
analogs), face a conflicting set of challenges to be used successfully in both in vitro and 
animal experiments as outlined in Figure 3.1..  Metabolic glycoengineering originated in 
efforts to exploit N-acyl modified monosaccharides – epitomized by using N-
acetylmannosamine (ManNAc analogs) to target the sialic acid pathway – to redecorate 
the cell surface with non-natural sugar epitopes (2, 3).  The versatility of metabolic 
glycoengineering was expanded considerably when the Bertozzi group used 
monosaccharide analogs to install bioorthogonal chemical functional groups into the 
glycocalyx of living cells in the form of ketone (4) and azide groups (5).  Finally, the 
chemical options available through this technique have continued to expand with the 
recent metabolic incorporation of thiols (6), aryl azides (7), alkynes (8), and diazarines 
(9) into cell surface displayed glycans.   
There are many potential biomedical applications for metabolic glycoengineering 
ranging from imaging, diagnosis, to the treatment of diseases ranging from cancer (10, 




Unfortunately the in vivo use of non-natural monosaccharide analogs has been slowed by 
low efficiency by which cells take up and metabolize these compounds;  typically 
concentrations in the tens of millimolar are required in cell culture, which translates to 
unacceptably high doses for large animal studies.  This pitfall has been rectified in part by 
the introduction of short chain fatty acid (SCFA) protecting groups, most commonly 
acetate, into analog design to increase cellular uptake by 600 to 900-fold (15, 16); we 
have found that metabolic efficiency can be increased further, by ~1,800 and 2,100 fold 
for propionate- and butanoyl-modified hexosamines, respectively (17).  This protecting 
group strategy that renders the core sugar more lipophilic and plasma membrane 
permeable is contingent the hope that the SCFA moieties will be ignored by extracellular 
esterases and lipases and reach the targeted cell unscathed.   
The extracellular stability of a SCFA-protected monosaccharide prodrug is important 
for two reasons.  First, when the primary intention is for the compound to enter a cell to 
intercept a glycosylation pathway, the SCFA moieties that enhance membrane 
permeability must remain attached to the core sugar until the analog reaches the 
membrane of the target cell.  Alternately, if the intention is to elicit “whole molecule” 
therapeutic effects exhibited by some analogs (e.g., by Bu4ManNAc or 3,4,6-O-
Bu3ManNAc (Fig. 3.1.B) as described in more detail below and in other publications (18-
20)), the exact pattern of regioisomeric SCFA derivatization must remain intact until the 
analog has time to interact with a target cell.  To illustrate this concept with a specific 
example, if the C6-substitutent of Bu4ManNAc were hydrolyzed extracellularly, certain 
of the resulting molecules (e.g., 1,3,4-O-Bu3ManNAc, Fig. 3.1.C) would not be able to 




is a facile intermediate for further debutanoylation and incorporation into the sialic acid 
pathway and thus actually increases the oncogenic propensities of late stage cancer cells 
by increasing the sialylation of adhesion molecules implicated in metastasis (22). 
Once a sugar analog used in metabolic glycoengineering is taken into a target cell, the 
SCFA protecting groups must be fully removed for the core sugar to intercept the 
targeted glycosylation pathway (which can also, in addition to sialic acid pathway 
targeted by ManNAc analogs in the current study), include the biosynthetic routes for 
fucose, GalNAc, or O-GlcNAcylation (14)). Thus, unlike in the extracellular milieu 
where the analog will ideally be refractory to hydrolysis of the SCFA groups, rapid 
deprotection inside the cell is necessary for facile metabolic glycoengineering of cellular 
glycans.  This paper addresses these issues by providing experimental evidence that 
esterase/lipase inactivation of SCFA-derivatized ManNAc analogs is relatively slow 
outside of a cell (Fig. 3.1.A) allowing these compounds to be used for routine in vitro cell 
culture and, most likely in vivo applications, without undue concern for rapid 
degradation.  By contrast, once taken up by a cell, esterase processing of analogs is 
relatively fast; or, to put it another way, cells have ample esterase activity to ensure that 
analog processing IS NOT the rate limiting step for the incorporation of SCFA-







3.2 MATERIALS AND METHODS 
3.2.1. Cell Culture and Seeding 
3.2.1.1. Human Pancreatic Adenocarcinoma (SW1990) Cells 
Human pancreatic cancer cells (SW1990; CRL-2172; ATCC; Gaithersburg, MD) were 
cultured in Dulbecco’s modified Eagle’s Medium (DMEM; Cellgro, Mediatech, Inc) 
supplemented with 10% FBS and 1% of a 100x penicillin/streptomycin stock solution. 
Cells were typically incubated in T-75 or alternatively in T-175 and T-25 flasks in a 5% 
CO2, humidified environment at 37 ˚C. These adherent cells were always kept at a 




 to prevent them from reaching a confluent and quiescent 
growth stage. The cells were passaged every 2 days by aspirating the spent media, 
washing cells with 10 ml of phosphate buffer saline (PBS; pH=7.4), adding 2-3 ml of 
trypsin (TrypLe™ Express, Invitrogen), incubating in a 5% CO2, humidified environment 
at 37 ˚C for 5-10 min, adding 10 ml of DMEM, transferring the cells to a 15 ml conical 
tube, centrifuging for 5 min at 1000g, aspirating the media, and resuspending in desired 





and incubated in a flask at 5% CO2, humidified environment at 37 ˚C. 
3.2.1.2. Analog Treatment  
Stock solutions of Bu4ManNAc (100 mM), Ac4ManNAc (100 mM) and 1,3,4-O-
Bu3ManNAc (100 mM), were prepared in filtered ethanol and stored at 4 ˚C. Appropriate 






3.2.2. Measuring the Number of Cells Using the Z2™ Coulter Counter 
After incubation, the spent media was aspirated, and the cells were washed with PBS. 
Trypsin was added and the plate was incubated in a 5% CO2, humidified environment at 
37 ˚C for 7 min. Then, DMEM media was added and the cells were then immediately 
counted using a Z2™ Coulter Counter (Beckman-Coulter, Brea, CA) with a 100 µm 
aperture, dilution factor of 1:101, and boundaries set between 7 and 25 µm. 
3.2.3. Periodate Resorcinol Assay Used to Determine Sialic Acid Flux 
A modified version of the periodate-resorcinol assay, originally described by Jourdian 
and co-workers, was used to determine sialic acid flux (16-18, 23). Treated cells were 
harvested with trypsin, washed twice with PBS, counted with the Z2 particle counter, and 
normalized such that equal amounts of cells (at least 1,000,000) were in each sample. 
Samples were freeze-thawed three times to lyse the cell membrane. The lysates were then 
oxidized with 0.4 M periodic acid and cooled on ice for 10 min. A resorcinol mixture 
containing 10% 0.5 M resorcinol, 10% 2.5 mM CuSO4, 44% concentrated HCl, and 36% 
de-ionized H2O was prepared. After oxidation, 500 µl of the resorcinol mixture was 
added to each sample and samples were heated at 100 °C for 10 min. After quickly 
cooling the heat block on ice, 500 µl of tert-butyl was added to each sample. The samples 
were then centrifuged for 2 min at 13000g and the absorbance was measured at a 
wavelength of 630 nm using a spectrophotometer. The sialic acid concentration was 
determined in each sample using a simultaneously developed standard curve that 
contained absorbance values at 630 nm of known concentrations (generally ranging from 




3.2.4. Inactivation Time Course for Analogs in Different Concentrations of Fetal 
Bovine Serum 
3.2.4.1. Materials Preparation 
FBS free DMEM media was prepared. This FBS free media was then supplemented with 
FBS to give 10% and 25% FBS solutions. For pretreatment the volume of the 100% 
FBS/10% FBS/25% FBS solution was chosen such that when it was added to the FBS 
free media and made up to 2 ml the final media’s FBS content was 10% FBS which is the 
standard media composition for SW1990 cells. The amount of analog added was so as to 
make the concentration of the final 2 ml solution up to the desired concentration. 
3.2.4.2. Pretreatment of Analogs With Fetal Bovine Serum 
The Bu4ManNAc, Ac4ManNAc and 1,3,4-O-Bu3ManNAc analogs were incubated in 
Fetal Bovine Serum (FBS) for different time periods (1 h, 2 h, 4 h, 24 h and 48 h) at 5% 
CO2, humidified environment at 37 ˚C. The incubations were initiated such that all the 
pretreatments end at the same time. The SW1990 cells were used as an indicator cell line; 
these cells were seeded in six well plates at a seeding density of 10
6
 cells per well as 
described in section 2.3.1.1., and allowed to grow on the plate for 24 h at 5% CO2, 
humidified environment at 37 ˚C. This seeding was done such that the 24 h incubation 
coincides with the end of the analog pretreatment.  
3.2.4.3. Exposing Cells to Pretreated Analogs 
The media was aspirated for each of the wells after which the required amount of FBS 




that the final volume was 2 ml with the analog at the desired concentration. The cells 
were then incubated for 48 h at 5% CO2, humidified environment at 37 ˚C. 
3.2.4.4. Quantification of Amount of Sialic Acid Produced by Periodate-Resorcinol 
Assay 
The cells are harvested and analyzed using the modified periodate-resorcinol assay 
outlined in section 2.3.3. The amount of sialic acid per cell is determined and the 
different time points are compared to the control (untreated) and the 0 h (un-pretreated) 
conditions. 
3.2.5. Statistical Analysis 
Experimental values are presented as means ± standard deviations or standard error 
mean. Each experiment above was repeated at least three times with a minimum of three 
technical replicates. In normalized data, all data points are normalized to the mean of the 
controls after which a one way ANOVA with a dunnett’s post-test was performed using 
GraphPad Prism v5 (La Jolla, CA). A p-value of less than 0.05 was considered 
statistically significant. 
 
3.3 RESULTS AND DISCUSSION 
In the first set of experiments a functional assay was used to monitor the effects of 
analog incubation in fetal bovine serum. This assay, which has been described in detail 
previously in a study of Ac4ManNAc uptake from tissue culture medium and 




SCFA groups, which reduces cellular uptake of the core sugar and subsequently results in 
a measurable decrease in sialic acid biosynthesis compared to control cells incubated with 
non-esterase or serum-treated analog.  Ac4ManNAc was refractory to serum inactivation 
over a 48 h time period (Fig. 3.2.A), thereby providing evidence that peracetylated 
monosaccharides widely used in metabolic glycoengineering are sufficiently resistant to 
serum esterases for a wide range of in vivo applications.  For example, in some 
applications such as treatment of hereditary inclusion body myopapthy (HIBM) with 
exogenously delivery ManNAc, sialic acid production peaked as soon as four hours after 
administration of Ac4ManNAc (24) while in other cases the administration of SCFA-
derivatized ManNAc analogs, e.g., Ac4ManNProp, required repeated daily administration 
over several weeks to achieve maximal in vivo replacement of natural sialic acids with 
the non-natural, metabolically engineered counterparts (25). 
Despite the serum stability of acetylated ManNAc analogs, butanoylated analogs have 
the advantage of 3- to 4-fold more efficient metabolic incorporation (17, 26) and 
importantly, offer added bioactivity of potential therapeutic value.  For example, 
hydrolyzed n-butyrate can provide therapeutic benefit by functioning as a histone 
deacetylase inhibitor (27, 28). In addition, “whole molecule” activity – where biological 
responses emanate from the intact compound before esterase processing occurs – 
exemplify an emerging concept that sugar-based templates offer an attractive platform for 
drug development (29); the whole molecule effects of butanoylated hexosamines include 
suppression of NF-κB and metastatic oncogenes (21) and are described in more detail 
elsewhere (18-20).  In the current work I found that fully n-butanoylated ManNAc 




the butanoylated analog showing a measurable reduction in sialic acid production in 
indicator cells after exposure to FBS for less than four hours while the acetylated sugar 
was stable for 48 h, the maximal time interval tested (Fig. 3.2.A).  The reduction in sialic 
acid production observed for Bu4ManNAc required the removal of at least 2 of the 4 
butyrate groups during the pre-incubation period, which renders the dibutanoylated 
analog membrane impermeable.
18
  By contrast, lower concentrations of FBS (e.g., 10% 
or 25%) did not result in a statistically significant reversion of Bu4ManNAc-enhanced 
sialic acid production in the indicator cells (Fig. 3.2.B).  These results have two 
implications: one is that under typical in vitro cell culture conditions, extracellular 
degradation of butanoylated analogs is not a substantial concern.  Conversely, 
extrapolating the 100% serum treatment condition to the in vivo milieu (because, 
disregarding the cells present, blood can be regarded as 100% serum), the degradation of 
butanoylated analog after only a few hours shows that the in vivo stability of these 
compounds is a potential concern when translating metabolic glycoengineering to animal 
studies.  However, pending detailed pharmacokinetic evaluation (which is beyond the 
scope of the present report), the half life of butanoylated analogs is “in the ballpark” for 
at least some in vivo applications (e.g., the ~ four hour kinetics for maximal sialic acid 
production observed in the Ac4ManNAc-treated HIBM mouse model (24)).  
The finding that Bu4ManNAc likely has only marginally sufficient serum stability for 
effectively eliciting “whole molecule” effects in vivo raised the concern that 
tributanoylated analogs with otherwise favorable properties (for example, 3,4,6-O-
Bu3ManNAc has stronger “whole molecule” responses than Bu4ManNAc (19, 20) and 




cytotoxicity (18, 26)) might be even more rapidly inactivated by extracellular esterases.  
To evaluate this possibility, I compared 1,3,4-O-Bu3ManNAc and 3,4,6-O-Bu3ManNAc 
against the parent compound Bu4ManNAc in relevant assays.  First the high flux analog 
1,3,4-O-Bu3ManNAc did not lose its ability to supplement sialic acid production 
noticeably faster than Bu4ManNAc, showing only a relatively minor reduction in analog-
enhanced sialic acid production after four hours of serum treatment (Fig. 3.2.C), which 
was similar to the kinetics observed for the perbutanoylated analog (as shown in Fig. 
3.2.B).  Similarly when growth inhibition, a “whole molecule” property of 3,4,6-O-
Bu3ManNAc (18), was tested by monitoring the number of cells present after various 
time intervals of serum pretreatment, comparable kinetics were observed where loss of 
analog-enhanced cell growth inhibition began to be manifest between 2 and 4 hours, with 
a complete reversal after 24 hours (Fig. 3.2.C). 
As a final test of extracellular esterase processing of ManNAc analogs, I evaluated 
azido-modified analogs pioneered by the Bertozzi group who first exploited them in 
modified Staudinger bio-orthogonal reactions (5); these compounds are now increasingly 
being used for metabolic glycoengineering because of their ability to be exploited in click 
reactions after installation into cellular glycoconjugates.  By testing surface expression of 
azido-modified sialic acids in indicator cells, both Ac4ManNAz and Bu4ManNAz were 
refractory to a loss of signal over the first four hours of FBS treatment but did experience 
a reduction, but not complete reversal, of surface expression after 24 hours of pre-
treatment (Fig. 3.2.D).  This assay suggested that the butanoylated analog Bu4ManNAz 
was more refractory to serum deactivation than Bu4ManNAc, possibly because the 




esterase(s).  Despite this ambiguity, this result established that azido-modified analogs 
are not rapidly (e.g., within minutes) deactivated by serum enzymes but instead should 
again have sufficient longevity for in vivo applications using once a day (or less frequent) 
dosing regimens.  
The requirement that intracellular esterase activity – in contrast to extracellular 
esterase activity as outlined above – occurs rapidly and thus is not a rate limiting step for 
sialic acid production was confirmed experimentally by monitoring production of this 
monosaccharide in cells treated with butanoylated ManNAc analogs over early time 
points.  This issue is relevant because in organisms such as Escherichia coli strains that 
lack robust non-specific esterase activity, the strategy of providing esterified precursors 
for metabolic engineering is not viable (30).  In my experiments in human cells, the 
perbutanoylated analog Bu4ManNAc, the “high flux” analog 1,3,4-O-Bu3ManNAc, and 
the 3,4,6-O-Bu3ManNAc analog with enhanced “whole molecule” effects all gave rise to 
statistically identical levels of increased sialic acid production over the first 12 hours 
(Fig. 3A).  These data diverge from previous results that showed that each compound 
supported different levels of sialic acid production when measured after 2 to 3 days of 
exposure to analog; for example, 1,3,4-O-Bu3ManNAc was dubbed the “high flux” 
analog because of the very high sialic acid levels found in cells after 48 to 72 hours or 
exposure (18, 26).  The current results indicate that this analog does not necessarily 
support a higher rate of metabolic flux per se, but instead the high levels of sialic acid 
observed in analog-treated cells after extended exposure are likely a consequence of the 
lack of cytotoxicity of this analog.  For context, analogs that inhibit the robust growth of 




amounts of sialic acid observed after 2 or 3 days of exposure to Bu4ManNAc or 3,4,6-O-
Bu3ManNAc likely result from the cytotoxicity of these analogs and not because esterase 
processing is a rate limiting step for incorporation into the sialic acid pathway.  Instead, 
in mammalian cells downstream enzymes such as sialic acid synthase likely comprise a 
bottleneck for ManNAc-supported flux through the sialic acid biosynthetic pathway (32, 
33). 
To address a final loose end, I was curious about the apparent disparity (albeit a 
fortunate one) where esterase cleavage of SCFA groups was much slower extracellularly 
(e.g., at least four hours was generally needed to remove one or two SCFA groups, Fig. 
2) than intracellularly (where, as shown in Figure 3.3.A, sialic acid production was 
observed within two hours for butanoylated ManNAc analogs.  We have previously 
reported similar kinetics for intracellular sialic acid production from Ac4ManNAc (34), 
which is only possible upon complete removal of SCFA groups from the core sugar.  One 
explanation for these results is that the enzymes implicated in detoxification and most 
likely analog processing, such as human carboxylesterase 1 (hCE1), are intracellular 
while extracellular enzymes (e.g., butylcholinesterases) are not capable of facile 
hydrolysis of SCFA from monosaccharides.  A second non-exclusive explanation is 
based on in silico docking simulations performed with AutoDock (following previously 
described procedures(19)) to evaluate the interaction of Ac4ManNAc (-2.9 kcal/mol and 
Kd = 7.2 mM) and Bu4ManNAc (-4.1 kcal/mol and Kd = 0.9 mM) with hCE1.  While 
relatively weak, these binding values fall within the range of other carbohydrate ligands 




attractive mechanism to explain why SCFA-ManNAc analogs are hydrolyzed slowly 
outside of a cell when in solution but rapidly inside a cell.   
To explain in more detail, analog concentrations are sketched in Figure 3.3.B, 
showing that the nominal concentration in solution in culture medium is below the Kd for 
binding to hCE1 (e.g., 0.9 mM for Bu4ManNAc) at concentrations typically used in 
metabolic glycoengineering experiments (e.g., <200 µM).  As a result, the extracellular 
processing of the analog is slow and inefficient.  Considering, however, that cellular 
membranes act as sinks for peracetylated ManNAc analogs (16) and this effect is 
exacerbated for the more lipophilic butanoylated analogs, we were able to extrapolate 
membrane concentrations for these compounds based on log P values calculated by 
ChemDraw.  Specifically, tributanoylated analog concentration is expected to be enriched 
at least 12-fold in membranes compared to aqueous solution with an additional ~20 fold 
gain (to ~239 fold in total) for perbutanoylated analogs.  Because hCE1 is a membrane 
associated enzyme, it is reasonable that the local concentration of analog near membranes 
thereby becomes sufficiently high to meet or exceed the in silico predicted Kd for this 
enzyme for concentrations of butanoylated analogs added to culture media in the 25 to 
200 µM range typically used.  Overall, although speculative at present, this mechanism 
satisfactorily explains the slow extracellular processing of analog (because, even if 
appropriate esterases are present in serum, analog concentrations in solution are 
considerably below the Kd, resulting in slow processing) as well as the facile intracellular 
processing (as just explained by the membrane sink effect). 
In summary, this report provides experimental evidence based on an in vitro model 




substrates – the potential rapid extracellular or the too slow intracellular esterase-
mediated removal of the SCFA groups – are not a major concern.  Consequently, this 
work provides a foundation for the continued development of metabolic glycoengineering 
by establishing a rationale for expanded translation from the “chemical glycobiology” 
origins of this methodology into more disease oriented animal model systems and 
biomedical applications. 
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Figure 3.1. Overview of extra- and intracellular processing of SCFA-hexosamine analogs.  (A) The lead 
compound Bu4ManNAc is used for illustrative purposives; outside of a cell if extracellular esterase/lipase 
degradation is relatively slow (left) then the intact molecule will enter the cell, otherwise if extracellular 
ester hydrolysis if relatively fast (right) a partially degraded metabolite such as 3,4,6-O-Bu3ManNAc will 
enter a cell. (B) In either case the butanoylated analog is subject to further esterase processing to 
ultimately produce fully deprotected ManNAc: alternately 1,3,4-O-Bu3ManNAc (or other partially 
deprotected intermediates, not shown) can be produced and similarly be deprotected to produce natural 
ManNAc (C), which is used by the sialic acid biosynthetic pathway (outlined in detail elsewhere 
14,35
) to 
produced sialic acid and sialylated glycans. (D) Although illustrated with butanoylated ManNAc, similar 
considerations apply to peracetylated ManNAc (illustrated) and its hydrolysis products as well as N-acyl, 





Figure 3.2. “Extracellular” esterase processing time course comparing various SCFA-derivatized 
ManNAc analogs. Several lines of evidence establish that SCFA-ManNAc analogs are relatively refractory 
against extracellular esterase/lipase hydrolysis: (A) Enhanced sialic acid production emanating from FBS-
treated Ac4ManNAc continued for much longer (e.g., ≥ 48 h) compared to Bu4ManNAc (e.g., for ~ 2 to 4 
h); (B) Under conditions encountered in typical cell culture, e.g., with 10% (or even 25%) FBS, 
butanoylated ManNAc was resistant to esterases/lipase degration. (C) Tributanoylated ManNAc analogs 
showed moderate resistance to FBS degradation with the “1,3,4” analog evaluated in the sialic acid flux 
assay used in panels A and B while the “3.4,6” analog was tested by evaluating enhanced cytotoxity of 
analogs, measured by cell counts, with this particular SAR.  (D) Azido-derivatived ManNAc analogs are 
shown (note that the structures of analogs used in panels A-C are given in Figure 1) along with surface 
labeling of Ac4ManNAz and Bu4ManNAz that had been pretreated with FBS. Analogs were synthesized and 
characterized as previously described: Ac4ManNAc and Bu4ManNAc;
17
 1,3,4-O-Bu3ManNAc and 3,4,6-O-
Bu3ManNAc;
18
 and Ac4ManNAz and  Bu4ManNAc.
25
  All data shown represents a minimum of n = 3 
replicates; the “*” symbol indicates p < 0.05 compared to the control and the double “**” symbols in 
panel D indicate a statistical difference (p < 0.05) at 24 h p < 0.05 compared to both the control and 





Figure 3.3. Intracellular esterase processing and an explanation for slow extracellular and fast 
intracellular analog hydrolysis. (A) Sialic acid production in LS174T “indicator cells” incubated with 
different forms of butanoylated ManNAc analogs shows statistical no difference over the first several 
hours.  (B)  Theoretical explanation for the slow extracellular and rapid intracellular processing of SCFA-
ManNAc analogs: tributanoylated and Bu4ManNAc concentrations are estimated in solution and in (or 
near) membranes based on logP values calculated with ChemDraw.  The Kd for association with hCE1 (a 
plausible model esterase) indicated with the dashed line, showing that the nominal concentration for 
analog in solution in media is typically below this threshold resulting in slow extracellular hydrolysis of 
SCFA groups while membrane-associated analog is typically at concentrations higher than this threshold, 
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PHARMACOLOGICAL MODULATION OF 
INTRACELLULAR ESTERASE ACTIVITY THROUGH 
METABOLIC GLYCOENGINEERING OF SIALIC ACID 
 
ABSTRACT 
This chapter describes the pharmacological manipulation of intracellular esterase 
activity in human colon cancer (LS174T) and Chinese hamster ovary (CHO) cells by 
using butanoylated ManNAc analogs. In the first part of this study in silico analysis of 
intracellular esterases, in particular the carboxylesterases (CES1 and CES2) implicated in 
drug processing and detoxification, supported the hypothesis that these enzymes are 
modified with sialylated N-glycans that stabilize their active trimeric forms.  
Experimental support for this premise was obtained by enhancing esterase activty by 
treating cells with ManNAc analogs that increase sialylation whereas hexosamine analogs 
not targeted to the sialic acid biosynthetic pathway (e.g., butanoylated GlcNAc or 
GalNAc) had minimal or negligible impact on esterase activity.  Characterization of 
mRNA and protein levels provided additional evidence that esterase activity was 
controlled at the level of post-translational modification and not through transcription or 
translation.  Azide-modified ManNAc analogs, which are now widely used in metabolic 
glycoengineering, also enhanced esterase activity and provided unambiguous evidence 




the glycan structures attached to esterases such as CES2. These results establish that 
sialylation with both natural and non-natural metabolic precursors controls the activity of 
intracellular esterases in ways relevant for the treatment of disease and compatible with 
emerging efforts to employ recombinant forms of these enzymes in biomedicine. 
 
4.1 INTRODUCTION  
Esterases are a versatile group of enzymes that contribute to several human diseases 
and play a significant role in drug metabolism; for example, these enzymes often degrade 
pharmacological agents and decrease drug effectiveness. Therefore, as discussed in a 
recent review,(1) selective inhibitors of esterases in theory could beneficially modulate 
the metabolism, distribution, and toxicity of pharmacological agents processed by this 
class of enzymes.  Accordingly, the development of inhibitors – in particular for the drug 
processing human carboxylesterases 1 and 2 (hCES1 and hCES2) is now recognized as 
an important research area and efforts to develop these compounds are underway (1). 
At other times, however, there is a need to maximize esterase activity.  For example, 
degradation  of intoxicants such as cocaine by esterases such as carboxylesterases 1 and 2 
(CES1 and CES2) provides a protective mechanism for the host(2,3). In other situations, 
prodrugs rely on esterase processing to be converted to their active form; examples of 
esterase-activated drugs include acetyl salicylic acid (aspirin) (4) and CPT-11, a 
semisynthetic derivative of camptothecin, which is activated to SN-38 by 
carboxylesterases (5,6).  Yet another area where the ability to enhance esterase activity 




examples include congenital mutations that impact esterase activity (7), reduced esterase 
activity that hinders monocyte-mediated killing of tumor cells (,8) and down-regulation 
of esterases in certain types of cancers when undergoing treatment with esterase-activated 
prodrugs (9).  Unlike the situation for esterase inhibitors, however, where several 
examples of inhibitors are known (1), the development of pharmacologically useful small 
molecule esterase activators is virtually non-existent (10-12). 
Accordingly, it was an intriguing possibility that sugar analogs used in metabolic 
glycoengineering (MGE), which comprise an emerging class of drug candidates that 
exemplify the idea that monosaccharides are a versatile template for drug discovery (13-
15), could be used to enhance the activity of intracellular esterases implicated in drug 
metabolism and disease progression. To briefly elaborate on MGE, which is also referred 
to as metabolic oligosaccharide engineering (MOE (16,17)), in vivo applications of this 
strategy were largely pioneered by Reutter’s group (18) who showed that exogenously-
supplied, non-natural sugars could be introduced into biosynthetic pathways to modulate 
glycosylation (17,19).  Because these sugars often lack plasma membrane transporters, a 
common strategy to increase cellular uptake has been to add ester-linked short chain fatty 
acids (SCFA) such as acetate (20,21) and more recently n-butyrate (22,23) to the core 
sugar.  The SCFAs increase the lipophilicity of the sugar and facilitate passive diffusion 
across the plasma membrane thereby bypassing the need for transporter-mediated intake. 
Once inside a cell, esterases remove the SCFAs over a period of hours (24), allowing the 
sugar to intercept the targeted glycosylation pathway and, by altering cellular 




integrins and CD44 as we have shown in previous work (25) and in this work, the drug-
processing esterases themselves. 
 The most highly glycosylated esterases (AChE and BChE, as mentioned above) have 
a minimal role in intracellular drug detoxification or processing (26) because they are 
secreted.  Nevertheless AChE and BChE provide precedent that glycosylation can be an 
important modulator of esterase activity and we were curious whether this principle 
extended to intracellular esterases.  In particular, reports that an N-linked oligosaccharide 
is located at the interface between CES monomers (27,28), as well as an in silico analysis 
we present in this report that revealed that virtually all cellular esterases are subject to 
glycosylation led us to propose that MGE analogs that manipulate glycosylation broadly 
modulate esterase activity.  In this study, this hypothesis was evaluated by a series of 
experiments that verified that an increase in aggregate esterase activity occurs within 
ManNAc analog-treated cells consistent with a key role for sialylation of intracellular 
esterases, in particular carboxylesterases CES1 and CES2.   
 
4.2 MATERIALS AND METHODS 
4.2.1 Prediction of N-glycan site occupancy using NetNGlyc 1.0.  
FASTA formatted amino acid sequences were attained from the NCBI database 
(http://www.ncbi.nlm.nih.gov). Sequences were attained for Carboxylesterase 1 
(Accession no. AAI10339), Carboxylesterase 2 (Accession no. AAH32095), 
Carboxylesterase 3 (Accession no. ACD11491), Carboxylesterase 7 (Accession no. 




(Accession no. AAA68151), Butyrylcholinesterase (Accession no. AAH18141), 
Carboxyl Ester Lipase (Accession no. AAA51973) and Esterase D (Accession no. 
AAC99788). These sequences were entered into the N-glycosylation prediction tool: 
NetNGlyc (http://www.cbs.dtu.dk/services/NetNGlyc/) and this online software tool then 
was used to predict the sites and probabilities of N-glycosylation. 
4.2.2 Modeling of N-Glycosylation of CES1 with Discovery Studio.  
The “Build Fragment” and molecule sketching capabilities of Accelrys Discovery Studio 
3.5 Visualizer were used to generate models of insect and human glycans into the crystal 
structure from PDB ID 1YA8 after water and other small molecules were removed. Initial 
models were minimized with a Dreiding-like forcefield to optimize geometries. 
4.2.3 Cell culture and incubation with sugar analogs.  
LS174T (ATCC
®
 CL-188) cells were grown in Minimal Essential Medium Eagle 
supplemented with heat-inactivated 10 % fetal bovine serum (FBS), 100 units/mL 
penicillin and 100 μg/mL streptomycin (pen/strep), 1x (100x dilution of 100x stock) non-
essential amino acids, and 110 mg/mL sodium pyruvate (Invitrogen, Carlsbad, CA). 
Chinese hamster ovary (CHO) cells - wild-type (WT, gift from the Betenbaugh 
laboratory, JHU), K1 (ATCC
®
 CCL-61), Pro-5 (ATCC
®
 CRL-1781), and Lec2 (gift from 
the Betenbaugh laboratory, JHU) were cultured in Dulbecco’s modified Eagle’s medium 
(DMEM) supplemented with heat-inactivated 10% FBS, penicillin/streptomycin 
(Pen/Strep) solution, and 2.0 mM L-glutamine. SCFA hexosamine analogs were 
synthesized and characterized using published methods (Bu4ManNAc (22), 1,3,4-O-
Bu3ManNAc and 3,4,6-O-Bu3ManNAc (14,29), and 1,3,4-O-Bu3ManNAz and 3,4,6-O-




ethanol (EtOH)) were added to 6-well tissue culture plates and the EtOH was allowed to 
evaporate.  Cells were suspended in 2.0 mL of culture media and then added to each well 
and incubated with the sugar analogs for time periods up to 48 h.  
4.2.4 Intracellular esterase activity assay.  
Analog-treated cells were detached using 1.0 mL of enzyme free cell dissociation buffer 
(Millipore) and washed with D-PBS (Mediatech).  Cells (200,000 cells) were then 
incubated with 600 µL of 1.0 µM carboxy fluorescein diacetate (CFDA; Marker Gene 
Technologies) or 400 µM resorufin acetate (Marker Gene Technologies) in the dark at 
room temperature under gentle vibration for 40 min or 10 min respectively.  An aliquot 
(150 µL) of each sample was then loaded into a black 96 well plate and the fluorescence 
level was read using the Synergy™ 2 Multi-Mode Microplate Reader (Biotek).  For 
CFDA, the reader was set to excite 475 nm and read at 530 nm for CFDA whereas for 
resorufin acetate, the reader was set to excite at 540 nm and read at 590 nm. 
4.2.5 Tunicamycin treatment. 
LS174T cells were incubated with 0.125 µg/mL of tunicamycin (Sigma-Aldrich) for 24 
h. The appropriate volume of sugar analog was then added to each well to give 
concentrations ranging from 0 to 100 µM and the cells were then further incubated for 48 
h at which time intracellular esterase activity was measured as described above. 
4.2.6 Reverse transcription-polymerase chain reaction (rt-PCR).  
Total RNA was isolated using Trisol
®
 reagents (Gibco BRL) and reversed transcribed 
using the high capacity RNA-to-cDNA kit (Applied Biosystems). PCR amplifications 




AGGTCATCCCTGAGCTGAACGG-3’ (sense) and 5’-
CGCCTGCTTCACCACCTTCTTG-3’ (antisense); Acetylcholinesterase (ACHE),  5’-
TTCGCCCAGCGACTGATGCG-3’ (sense) and 5’-GCCATTGTGGGGCCTTGGGG-3’ 
(antisense); Butrylcholinesterase (BCHE), 5’-AGATCCATAGTGAAACGGTGGGCA-
3’ (sense) and 5’-TGAAGACAGGCCAGCTTGTGCT-3’ (antisense); Carboxyl Ester 
Lipase (CEL), 5’-GTGGGTTCGTGGAAGGCGTCAA-3’ (sense) and 5’-
GGAACCCAAGGGGGCCGACA-3’ (antisense); Carboxylesterase 1 (CES1), 5’- 
AGCGCAGGGCGGTAACTCTGG-3’ (sense) and 5’-
CGAGGACGGATGCCCTGCCCA-3’; Carboxylesterase 3 (CES3), 5’-
GGGCGTGAAGGGCACAGACC-3’ (sense) and 5’- CAGTGCTGGCATCCCGCACA-
3’ (antisense); Carboxylesterase 7 (CES7), 5’-
GCTCGATATCACAGAGAAGGAGCCA-3’ (sense) and 5’-
CCGGTTCGAGCAAAGGTAGCCC-3’ (antisense). qRT-PCR was performed using the 
Step-One Plus Real-Time PCR system (Applied Biosystems)  with the thermocycling 
conditions of 50 ˚C for 30 min, 95 ˚C for 10 min followed by 40 cycles of 95 ˚C for 15 s 
and 60 ˚C for 1.0 min. PCR amplification for carboxyesterase 2 (CES2) was performed 
using TaqMan® Gene Expression Assay (cat. No. 4331182, Applied Biosystems). 
4.2.7 Western blot analysis.  
Proteins were immunodetected using the following commercial antibodies: anti-CES1 
(AV41877, Sigma-Aldrich), anti-CES2 (514-621, Novus Bio.) and HRP-linked anti-




4.2.8 Intracellular immunofluorescence staining and flow cytometry.  
Analog treated cells were detached using 1.0 mL of enzyme free cell dissociation buffer 
and washed with D-PBS. The cells were then washed once with permeation buffer (D-
PBS, 2.0 % heat inactivated FBS, 0.2 % sodium azide, 0.5 % saponin), washed once with 
super-permeation buffer (3 parts permeation buffer to 1 part FBS) and fixed using 3.75 % 
formaldehyde in DPBS for 15 min. Cells were then washed twice with staining buffer 
(PBS, 2.0 % heat inactivated FBS, 0.2 % sodium azide) and incubated with human-
specific anti-CES1 (Sigma-Aldrich) primary antibody in permeation buffer for 1.0 h at 
room temperature. Cells were then washed with permeation buffer, incubated with FITC-
linked anti-rabbit antibody (Sigma-Aldrich) secondary antibody for 1.0 h and washed 
again with permeation buffer. The cells were then re-suspended in PBS and analyzed 
using the C6 Flow Cytometry system (Accuri Cytometers). 
4.2.9 Determination of sialic acid levels in analog-treated cells.  
Cells were incubated for 48 h and then lysed by subjecting them to three freeze-thaw 
cycles.  Lysates were analyzed using an adaptation of the periodate-resorcinol assay (31) 
to a 96 well plate format (32) to quantify total sialic acid.  For each experiment, test 
samples were compared to a standard curve created using known concentrations of N-
acetylneuraminic acid (Invitrogen). 
4.2.10 Click chemistry enrichment of azide-labeled proteins in ManNAz-analog 
treated cells.   
Cells (5.0 x 10
7
) were incubated for 48 h with 0 µM or 100 µM 1,3,4-O-Bu3ManNAz 
after which the cells were collected using 3.0 mL enzyme free cell dissociation buffer and 




Chemistry Tools from the Bioconjugate Technology Company).  Lysates were pelleted 
by centrifugation at 10,000 g for 5.0 min and the supernatant was collected.  Copper 
catalyst solution (1.0 mL of a 2x solution, Bioconjugate Technology Company) and 0.2 
mL of washed alkyne agarose resin (Bioconjugate Technology Company) were added 
and mixed on an end-over-end rotary shaker for 48 h at 4 ⁰C.  The resin was then washed 
10 times with agarose wash buffer (Click Chemistry Tools) using a spin column and 
centrifuging at 1,000 g for 1.0 min, the column then was washed 5 times with 8 M 
urea/100 mM Tris pH-8 and finally washed 5 times with 20% acetonitrile. The washed 
resin was then resuspended in 0.2 mL elution buffer (100 mM sodium phosphate with 2% 
(v/v) hydrazine) and incubated for 120 min at room temperature: during this step the 
hydrazine cleaves a Dde linker thus releasing the bound proteins from the agarose resin. 
The eluted solution was collected by centrifugation and analyzed by western blotting. 
4.2.11 Statistical analysis. 
Data was expressed as means ± standard error (SEM). Statistical significance was 
determined using one way ANOVA to compare means of different samples with control. 
The null hypothesis was rejected in cases where p-values were < 0.05. 
 
4.3 RESULTS AND DISCUSSION 
4.3.1 In silico evidence for glycosylation of intracellular esterases.  
The hypothesis that intracellular esterase activity can be modulated by MGE depends on 
the glycosylation of these enzymes.  To gain insight into this issue, we used NetNGlyc 




whether these enzymes are typically subject to this PTM.  As a positive control, this 
approach correctly predicted several already-known sites of N-glycosylation for ACHE 
and BCHE (Table 4.1) (10-12).  NetNGlyc analysis also showed that, with the exception 
of Esterase D (ESD), all esterases tested had at least one requisite consensus sequon for 
the biosynthetic installation of N-glycans and indeed, were predicted to be N-glycosylated 
based on the algorithm used by the NetNGlyc 1.0 software. 
The premise that intracellular esterase activity could be influenced by MGE was 
supported by anreport that liver carboxylesterases were glycosylated (33) as well as 
structural information suggesting that an N-linked oligosaccharide was located at the 
interface between CES1 monomers (27,28).  An apparent conundrum, however, is that 
carboxylesterases such as CES1 or CES2 are “intracellular” proteins, a class of molecules 
that generally are not N-glycosylated.  A conceptual solution to this discrepancy lies in 
the subcellular localization of these enzymes; under normal conditions they only partially 
transit the secretory apparatus and remain in the endoplasmic reticulum (ER) while 
removal of their ER-localization amino acid sequence is sufficient to allow for their 
secretion (34).  In essence, carboxylesterases exemplify extracellular proteins insofar as 
they are subject to N-glycosylation and are routed towards secretion; the secretion 
process, however, is thwarted by the ER-localization sequence that ultimately results in 
the retention of these esterases inside of a cell. 
4.3.2 In silico analyses of hCES glycosylation.  
N-glycosylation of human carboxylesterases has already been reported (27,28) but 
several uncertainties remain.  For example, only one (and in some cases two) GlcNAc 




sialic acid have been observed in crystal structures of hCES1 produced in Spodoptera 
frugiperda insect cells. We assumed that the sialic acid was a legitimate part of an N-
glycan chain attached to hCES1 because the free monosaccharide form of this sugar is 
only present in very low concentrations in biological milieu and unlikely to have co-
crystallized with the protein. Based on this assumption, we first ruled out that the 
positioning of sialic acid was due to crystal packing effects that do not represent the 
active form of this enzyme under normal cellular conditions.  As shown in Figure 4.2A, 
the distance between a proximal GlcNAc and the closet sialic acid moieties on an 
adjacent crystal unit is ~45 Å while the longest S. frugiperda N-glycan (as well as the 
majority of human N-glycans (35)) are < 25 Å when fully extended.  Based on this 
information, the sialic acid moieties observed in the published crystal structure can only 
plausibly be appended to N-glycan chains that are located within each trimeric assembly 
of CES1 that constitutes the active form of this enzyme in cells and are not a result of 
crosslinking due to crystal packing. 
Once we were confident that the sialic acid observed in the published structures was 
not simply an artifact of the crystallization process, we explored addition details of the 
trimeric form of CES1 as depicted in Figure 4.2B.  This figure shows location of the 
proximal GlcNAc on ASN97 at the interface of two CES1 peptide chains along with the 
closely-spaced but undefined sialic acid observed in the crystal structures, as explicitly 
illustrated in Figure 4.2B(i).  In another in silico approach, we modeled a typical N-
glycan structure at the interface between the two CES1 subunits (Figure 4.2B(ii)), which 
indicates that the glycan is not large enough that its terminal sialic acids could “reach” to 




the position shown in Figure 4.2B(i) nor is the glycan large enough to directly interfere 
with substrate binding (Figure 4.2B(iii)).  Therefore, the impact that the glycan has on 
catalysis – as described subsequently in this report – must occur via allosteric effects 
including quaternary-level stabilization of the trimeric form of the enzyme.    
Based on the evidence presented in Figure 4.2A and B, the sialic acid observed in the 
crystal structure of hCES1 could only plausibly be part of an N-glycan attached to nearby 
ASN97; the GlcNAc of this glycan proximal to this amino acid and the undefined sialic 
acid are shown at higher resolution in Figure 4.2C.  Because the connecting portion of 
the N-glycan between the proximal GlcNAc and terminal sialic acid was not observed in 
the crystal form of hCES1, we modeled representative N-glycans to determine if the 
proximal GlcNAc reasonably could be connected to the sialic acid, which was “pinned” 
to the close-by ASN97 site of attachment to the protein.  Although S. frugiperda cells 
(the source of crystallized CES1 in published studies) typically produce high mannose N-
glycans that lack sialic acid, Drosophila sialylate a small fraction of glycan structures (< 
10%), and can process ManNAc analogs into sialosides (36), These results suggest that 
insects do have a limited capacity for sialylation. with a single sialylation site on the α3 
antennary branch of N-glycans.  Therefore, we appended a sialylated arthropod N-glycan 
(37) to ASN79 and modeled this structure in an attempt to fill in the missing density 
between the non-reducing end of GlcNAc and the sialic acid. The entire glycan was 
minimized to correct for deviations in idealized geometries, and there were no geometric 
or steric difficulties in closing such a loop from GlcNAc to the terminal sialic acid, 




glycan to adopt the necessary configuration to locate the sialic acid in the position for a 
typical insect glycan, as indicated the published crystal structures (Figure 4.2D).  
Next, the α6 antennary branch of the singly sialylated arthropod glycan was extended 
by a β-Gal-6α-Neu5Ac unit to model a typical complex biantennary mammalian N-
glycan to increase the relevance of the modeling efforts to the experiments subsequently 
reported in this paper that were conducted in human and CHO cells.  These results show 
that the second sialylated arm of the N-glycan can easily extend away from the surface of 
the CES1 complex to facilitate the binding of the sialylated arm to the position where 
sialic acid was observed in the crystal structure (Figure 4.2E).  Finally, a fully 
fucosylated, triantennary N-glycan was modeled; although this particular glycan structure 
is not abundant we used it to represent an extreme case to ask whether the extra steric 
bulk from the added branching introduced by the third arm and fucose residues could 
prevent correct positioning of the sialic acid observed in the crystal structures.   The 
results of this simulation (as shown in Figure 4.2F), however, showed that the terminal 
sialic acid could still be properly positioned, illustrating how the hCES1 trimer can 
accommodate a broad range of N-glycans (including numerous examples not shown here) 
and still position the proximal GlcNAc and undefined sialic acid as observed in the 
published crystal structures. 
  These in silico results were significant from several perspectives.  First, they 
confirmed that CES1 can be N-glycosylated in a manner consistent with previously 
reported crystal structures and furthermore, that the observed sialic acid is legitimately a 
part of an appended N-glycan and not a serendipitously co-crystallized soluble sialic acid 




necessarily confined in space, which is unlike the connecting monosaccharide residues 
that were not observed in the crystal structure presumably because of a combination of 
rapid unconfined motion and the heterogeneity of N-glycan structures that connect the 
proximal GlcNAc residue with the terminal sialic acid.  Third, once the minimal 
requirement of having a sialylated α3 antennary branch is met (as evidenced by the 
arthropod glycan shown in Figure 4.2D), additional elaboration of the N-glycan structure 
that typically occurs in mammals is not detrimental for hCES1 subunit assembly because 
the “extra” oligosaccharide chains can be easily oriented away from the globular protein 
into open space.  Finally, the fact that sialic acid was observed in the crystal structures 
implies that sialylated N-glycans were over-represented in crystallized CES1 compared to 
their overall production in insect cells, which according to literature reports is 
comparatively minor.  Consequently, while only a relatively small fraction of the hCES1 
produced by the insect cells used to generate the crystals under discussion was expected 
to be modified with sialylated N-glycans, the under-represented sialylated species 
preferentially gave rise to the multimeric assemblies required for crystallization.    
All in all, the in silico modeling results led us to formulate a hypothesis wherein sialic 
acid plays a stabilizing role in CES1 trimer formation and provided impetus for the 
experimental efforts described in this report to increase esterase sialylation using a MGE 
approach.  Importantly, we had at our disposal ManNAc analogs that were expected to 
selectively modify sialic acid in a way predicted to increase esterase activity if our 
hypothesis was valid while corresponding hexosamines (e.g., GalNAc analogs) that do 




glycan branching) that our modeling suggested was not important for esterase activity 
would serve as negative controls. 
4.3.3 Increased esterase activity was observed in ManNAc analog treated cells.  
The evidence presented above suggesting that sialic acid-bearing species become 
enriched during crystal formation of CES1 was particularly intriguing because multimeric 
assembly this enzyme is required for catalytic activity (27,38).  These results implied that 
esterase activity – which depends on multimeric assembly – benefits from increased 
sialylation; accordingly, I reasoned that a ManNAc analog-based MGE approach that 
increases flux through the sialic acid pathway (22,29) and in turn increases protein 
sialylation (25,30), should increase esterase activity.  To test this prediction, indicator dye 
assays were used to evaluate the impact of “high flux” butanoylated ManNAc analogs 
that increase sialylation (25,29,30) on esterase activity.  At the outset, I was concerned 
that these assays might not be definitive because two factors had the potential to diminish 
the predicted increase in esterase activity.  First, if a substantial portion of intracellular 
esterase activity was occupied in activating the hexosamine analogs themselves (the 
esterase processing of SCFA-hexosamine analogs is discussed extensively in our 
previous publications (21,23,24,29)), signal derived from the indicator dyes might be 
suppressed. A high basal level of esterase activity therefore was desirable to ensure 
adequate signal for unambiguous results leading me to select the human colon 
adenocarcinoma LS174T line for these experiments because of their high esterase activity 
(6).   
The fluorescent dyes used to measure esterase activity in our assays are widely 




cells under test experience reduced viability as a consequence of well-established SCFA-
hexosamine cytotoxicity (22), the ensuing decrease in esterase activity could offset the 
predicted sialic acid-driven increase.  To avoid this possibility, two steps were taken.  
First, the analogs were used at sub-growth inhibitory doses (i.e., < 150 µM for 
Bu4ManNAc and 1,3,4-O-Bu3ManNAc and < 25 µM for 3,4,6-O-Bu3ManNAc).  Then, to 
deconvolute any remaining impact from the cytotoxicity of the analogs, initial 
experiments were performed with Bu4ManNAc, 1,3,4-O-Bu3ManNAc, and 3,4,6-O-
Bu3ManNAc because these three analogs have varying cytotoxicities(29) that would 
allow correlations between toxic analogs (Bu4ManNAc and 3,4,6-O-Bu3ManNAc) and 
trends in esterase activity to be deconvoluted if they existed.  These concerns, however, 
were rendered moot when independent assays using different indicator dyes (carboxy 
fluorescein diacetate, CFDA; Figure 4.3A or resorufin acetate; Figure 4.3B) both 
showed an increase in esterase-generated fluorescent signal.  This ManNAc analog-
driven increase in sialylation confirmed our prediction that increased sialylation would 
increase esterase activity, and furthermore, that the increased activity was sufficiently 
robust to outweigh any secondary effect by which these compounds could theoretically 
diminish esterase activity. 
4.3.4 Increased esterase activity is not correlated with gene expression or protein 
levels.  
As predicted from the in silico results shown in Figure 4.2, butanoylated ManNAc 
analogs that increase sialic acid also enhanced intracellular esterase activity (Figure 4.3).  
At the outset of the experiments, the most likely esterase responsible for the processing of 




although both CES1 and CES2 are implicated in drug detoxification and metabolism 
(26), robust CES1 expression is restricted to liver- and monocyte-derived cell lineages 
(39,40). However, because of conservation of important catalytic and structural residues 
(41), I reasoned that the impact of sialylation would be similar for both carboxylases and 
initially focused on testing CES2.  I found that neither gene or protein expression could 
explain the increase in esterase activity engendered by Bu4ManNAc, 1,3,4-O-
Bu3ManNAc, and 3,4,6-O-Bu3ManNAc by evaluating CES2 transcription (by qRT-PCR, 
Figure 4.4A) and translation (by western blot assays, Figure 4.4B) and found that 
Bu4ManNAc increased transcription roughly equivalent to the magnitude of increased 
esterase activity (e.g., to 150 to 200 % of controls, Figure 4.3).  The two tributanoylated 
analogs 1,3,4-O-Bu3ManNAc, and 3,4,6-O-Bu3ManNAc, however, did not increase 
transcription or translation of CES2 despite increasing esterase activity with 
approximately the same efficiency as Bu4ManNAc (see Figure 4.3).  Therefore I 
concluded that the Bu4ManNAc-driven increase in CES2 mRNA levels was either 
unrelated, unnecessary, or at most only a partial explanation for the increased esterase 
activity observed cells treated with butanoylated ManNAc analogs.   
An alternate explanation for the discrepancy between the inconsistent changes in 
transcription and translation of CES2 and the consistent overall increase in cellular 
esterase activity was that esterases other than CES2 played an unexpectedly large role in 
LS174T cells.  Accordingly, I expanded my analysis to additional esterases expressed in 
human cells and found that mRNA levels for several of these enzymes were either 
substantially down-regulated (e.g., for AChE, BChE, CEL, and CES3) or not affected 




regulation of several of these enzymes ran counter to the overall increase in esterase 
activity observed in ManNAc analog-treated cells, the specific esterases that experienced 
reduced mRNA levels have limited relevance to detoxification or drug metabolism.  
Therefore these esterases were not expected to process SCFA-hexosamine analogs or 
indicator dyes and thus were not expected to have a measurable effect in the fluorophore-
based assays.   
An important finding of the mRNA results was that CES1 was transcribed in the 
LS174T cell line, which was not expected a priori because, as mentioned above, CES1 is 
primarily associated with liver and monocyte-derived cell lineages rather than prostate 
cells.  However, reported epigenetic control of CES1 by methylation in cancer (42) 
provides a plausible explanation for the expression of this enzyme in LS174T cells in the 
current experiments.  To further probe the significance of CES1 transcription in these 
cells, western blot (Figure 4.4D) and immunofluorescence (Figure 4.4E) assays 
confirmed expression at the protein level.  Therefore, in addition to CES2, which started 
out as the most likely candidate for SCFA-hexosamine processing in LS174T cells, the 
remainder of this report considers CES1 as an esterase that both processes (as indicated in 
Figure 4.1), and is modulated by, SCFA hexosamine analogs.  All in all, because the 
mRNA and protein levels of CES1 were not affected by Bu4ManNAc, 1,3,4-O-
Bu3ManNAc, or 3,4,6-O-Bu3ManNAc, the mechanism of increased esterase activity in 
the analog-treated cells can best be explained by the glycosylation-based hypothesis 




4.3.5 Increased esterase activity was experimentally confirmed to be linked to 
glycosylation.  
Having discounted transcription or translation as the primary mechanism controlling 
esterase activity in ManNAc analog-treated cells, I next conducted experiments to 
confirm that the glycosylation of these enzymes contributed to the observed increased 
activity in cells.  In the first of these experiments cells were treated with tunicamycin, 
which is a compound that blocks N-glycosylation and inhibits liver carboxylesterase 
activity (33); as shown in Figure 4.5A tunicamycin prevented ManNAc analog-driven 
increases in esterase activity.  Furthermore, treatment of the cells with an expanded panel 
of hexosamine analogs, revealed manipulation of N-glycans with analogs that did not 
alter sialylation did not have an impact on esterase activity.  Specifically, butanoylated 
GalNAc and GlcNAc (i.e., Bu4GalNAc and Bu4GlcNAc, Figure 4.5B) had negligible and 
minimal effects on esterase activity compared to Bu4ManNAc respectively, (Figure 
4.5C) even though these analogs increase the production of UDP-GlcNAc, which is a 
critical building block for N-glycans and increase N-glycan branching (43).  It is 
noteworthy that the minimal, but measurable, impact of butanolylated GlcNAc was 
commensurate with the small increase in sialic acid detected in cells treated with this 
analog (Figure 4.5D) (the increased sialic acid is likely a consequence of GlcNAc 
epimerization to ManNAc, the committed feedstock for sialic acid biosynthesis (44)).  A 
final piece of evidence implicating sialic acid as the critical factor responsible for 
enhanced esterase activity was provided by supplementation with unmodified ManNAc 
(Figure 4.5E).  Although high levels (e.g., tens of millimolar) of unmodified ManNAc 




ManNAc analogs, the lower effectiveness of unmodified ManNAc was expected because 
it lacks the ability of butanoylated analogs to diffuse through the plasma membrane and 
efficiently enter cells (22).  Because the exclusive metabolic role of ManNAc is to supply 
flux into the sialic acid pathway, however, (unlike the butanoylated compounds that can 
have epigenetic effects (14,23)), this experiment strongly implicated sialylation as a 
critical and necessary determinant of enhanced esterase activity.   
4.3.6 Corroboration of the importance of sialylation in modulating esterase activity 
in CHO cells.  
The impact of ManNAc analogs on esterase activity was tested next in Chinese hamster 
ovary (CHO) cells because I was interested in how robust analog-mediated enhancement 
of esterase activity was across cell lines and even species.  I demonstrated that ManNAc-
driven enhancement of esterase activity is broadly evident in mammalian cells by testing 
wild-type (WT) CHO cells and finding an approximately equivalent increase in activity 
(e.g., roughly two-fold, Figure 4.6A) as seen earlier in human cells at similar 
concentrations of butanoylated ManNAc analogs (Figure 4.3).  Further, CHO mutant 
lines were available that allowed me to confirm qualitatively that the role of 
glycosylation (in general) and sialic acid (more specifically) was required for enhanced 
esterase activity.  Specifically, a comparison of three mutant CHO lines (as summarized 
in Table 2) was consistent with the observations from the human cells.  First, the K1 line 
that has mutations that ablate both N-glycan production and sialylation did not respond to 
butanoylated ManNAc analogs (Figure 4.6B).  Second, the CHO5 line, which has a 
reduced (but measurable) capacity for sialylation of N-glycans, showed an attenuated but 




supplementation.  Finally, the Lec-2 line, which has defective Golgi transport of CMP-
Neu5Ac that can be rescued by increased flux through the sialic acid pathway (e.g., via 
ManNAc analog supplementation in the current experiments), had a robust increase in 
esterase activity similar in magnitude to the WT cells.  An interesting facet of the CHO 
cell experiments was that although all ManNAc analogs solicited qualitatively similar 
responses, the two analogs with “whole molecule” activity (e.g., Bu4ManNAc and 3,4,6-
O-Bu3ManNAc as we discuss elsewhere (14,15,29)) increased esterase activity more than 
1,3,4-O-Bu3ManNAc.  Therefore, it is noteworthy that while ManNAc – and by 
extension sialylation – is a critical component of esterase modulation in the CHO cells, 
other factors (beyond the scope of this report) may also contribute to this phenomenon.  
4.3.7 Azido-modified sialic acids modulate esterase activity and are incorporated 
into CES2.  
Moving beyond the use of ManNAc analogs to increase the production of natural sialic 
acid as has been reported so far in this paper, many examples of MGE technology employ 
sugar analogs modified with non-natural functionalities.  One of the most common 
modifications involves the substitution of the natural N-acetyl group with an N-azido 
group (e.g., Bu4ManNAz or 1,3,4-O-Bu3ManNAz, Figure 4.7A) to install the 
corresponding azido-modified sialic acid into cell surface glycans.  I was curious if 
ManNAz analogs would enhance esterase activity in a manner similar to the “natural” 
ManNAc analogs described earlier in this report.  Accordingly, I tested Bu4ManNAz and 
1,3,4-O-Bu3ManNAz and found that both compounds increased esterase activity; 
furthermore the magnitude increase (up to about 2-fold greater than untreated controls) 




kinetics of the increase in esterase activity (e.g., over a ~ 2 day period) was consistent 
with the incorporation of various (e.g,. ketone (45) or azide-derivatized (30)) ManNAc 
analogs into glycoproteins.  The ability of azido-modified ManNAc analogs to increase 
esterase activity was extremely significant from the viewpoint that MGE technologies, 
such as those used in this study to modulate esterase activity, broadly impact dozens (or 
even hundreds/thousands) of cellular sialoglycoconjugates and – when using the natural 
form of ManNAc to increase sialylation – it is difficult to verify that CES1, CES2, or 
another esterase, is directly impacted.  The ability of azido-modified glycoconjugates to 
be used in click chemistry-based “pull-down” experiments (46) to identify glycoproteins 
that become labeled with the MGE sugar analog was exploited to resolve whether or not 
the sialylation status of CES was affected by ManNAc analog supplementation.  In this 
experiment, after cell lysates were pulled down by a click chemistry approach, analog 
incorporation into CES2 was confirmed by the western blot results shown in Figure 
4.7C), where signal was only detected in ManNAz analog-treated samples.  This 
experiment unambiguously establishes that ManNAc analogs can be incorporated into the 




This paper reports the discovery that monosaccharide analogs that increase sialic acid 
production elicit a concomitant increase in intracellular esterase activity consistent with 
the enhanced sialylation of the single N-glycan found on CES1 and CES2, the two 




demonstration that intracellular esterase activity can be modulated by MGE has several 
practical biomedical implications.  One is the direct use of SCFA-hexosamines as drugs; 
conceptually this idea is supported by the treatment of HIBM (a muscle disorder 
characterized by reduced sialic acid production due to a genetic defect in GNE (47)), 
where Ac4ManNAc has shown promise in a mouse model (48).  Encouragingly, the 
HIBM study establishes that this class of compounds has acceptable pharmacological 
properties to be used in vivo.  Moving forward, diseases characterized by insufficient 
esterase activity could be treated with ManNAc analogs to restore esterase activities.  A 
few examples include congenital mutations that reduce esterase activity (7), reduced 
esterase activity that hinders monocyte-mediated killing of tumor cells (8), and down-
regulation of esterases in certain types of cancers when undergoing treatment with 
esterase-activated  prodrugs (9). 
Another biomedical scenario where the correlation between sialic acid and esterase 
activity may prove important is provided by nascent efforts to produce recombinant 
versions of these enzymes (e.g., carboxylesterase CES2(34)), which could exploit 
ManNAc analog supplementation to maximize activity.  Finally, the ability of 
butanoylated ManNAc analogs to down-regulate transcription of AChE, BChE, CEL, and 
CES3 (as shown in Figure 4.4) may be valuable in several disease contexts; one example 
is attenuation of increased BChE activity associated with Alzheimer's disease (49,50).  
Overall, this paper demonstrates that hexosamine analogs that manipulate glycosylation 
can be used as small molecule, pharmacologically relevant agents to fill the current void 
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Figure 4.1. Overview of esterase processing of SCFA-derivatized ManNAc analogs and the subsequent 
impact on esterase activity. (A) Structures of butanoylated ManNAc analogs that readily enter cells 
through membrane diffusion where (B) drug metabolizing esterases remove their ester-linked n-butyrate 
groups to generate unmodified ManNAc, which (C) acts as a feedstock that increased metabolic flux 
through the sialic acid biosynthetic pathway.  (D) Increased sialylation is proposed to increase the activity 
of intracellular esterases as measured by (E) resorufin acetate (shown) or carboxy fluorescein diacetate 








Figure 4.2. In silico evaluation of CES glycosylation. (A) The hCES1 trimer and its closest crystal partner 
in the periodic image along the a axis. The a unit cell vector length is 55.78 Å. Glycan residues are shown 
as space-filling models and colored by element. The distance from a GlcNAc residue to the closest sialic 
acid residue is ~45 Å. (B) The hCES1 trimer with each monomer shown in a different shade of gray. Non-
peptide residues and molecules are shown as space-filling models and colored by element. Carbon atoms 
for saccharide residues are shown in standard CFG colors. Carbon atoms for the substrate analogs are 
shown in yellow. (C) Protein subunits A and B of hCES1 are shown using dark gray and light gray ribbons, 
respectively, from the published crystal structure(27), with Asn79 (labeled) along with the proximal 
GlcNAc and undefined sialic acid shown in the position observed in the published crystal structure.  (D–F) 
Protein subunits A and B of hCES1 are shown along with appended glycans representative of (D) an low-
abundance complex-type insect N-glycan w/ sialic acid, (E) a representative mammalian bis-sialylated 
complex N-glycan, and (F) a tri-antennary fully fucosylated mammalian N-glycan (All carbohydrate atoms 
in C–F are shown with sticks and colored by element with representations of glycans relevant to hCES 
activity determined using the CFG standard symbol notation generated using GlycoWorkbench.(51) 










Figure 4.3. Intracellular esterase activity activities measured by activation of fluorescent dyes. 
Fluorescence levels are shown for LS174T cells treated with Bu4ManNAc, 1,3,4-O-Bu3ManNAc, and 3,4,6-
O-Bu3ManNAc analyzed by two assays (A) carboxy fluorescein diacetate and (B) resorufin acetate. * - 





Figure 4.4. Transcriptional and translational control of esterases in LS174T cells. Quantification of 
CES2 protein and RNA levels from LS174T cells via (A) qRT-PCR and (B) western blot respectively 
showed that overall levels of this esterase remained unchanged upon sugar analog treatment, with the 
exception of Bu4ManNAc treatment where the signal increased. (C) qRT-PCR showed that mRNA levels for 
ACHE, BCHE, CEL, and CES3 in LS174T cells treated with Bu4ManNAc were significantly down-
regulated at higher concentrations while CES1 and CES7 were not affected.  Quantification of CES1 from 
LS174T cells via (D) western blots and (E) immunofluorescence assays using flow cytometry showed that 
the overall levels of this esterase either remained the same upon sugar analog treatment. * - indicates a P 





Figure 4.5. Expanded analysis of the effects of glycosylation on esterase activity. (A) Tunicamycin treated 
LS174T cells that were also treated with ManNAc analogs did not experience an increase in esterase 
activity.  (B)  Structures of Bu4GlcNAc and Bu4GalNAc analogs, which (C) elicited a small or no increase 
in esterase activity (respectively) in LS174T cells (Bu4ManNAc was included in this experiment as a 
positive control). (D) The periodate resorcinol assay was used to measure sialic acid content in 1,3,4-O-
Bu3GlcNAc-treated cells, with 1,3,4-O-Bu3ManNAc again used as the positive control (no increase in sialic 
acid levels was observed for GalNAc analog treated cells, data not shown). (E) Intracellular esterase 
activity in cells treated with increasing concentrations of unmodified ManNAc.   * - indicates a P value of 





Figure 4.6. Analysis of esterase activity in various analog-treated CHO cell lines. (A) Wild-type cells that 
treated with ManNAc analogs experienced an increase in esterase activity while (B) CHO-K1 cells did not 
experience a change in esterase activity under any condition; (C) Pro-CHO-5 cells demonstrated a less 
dramatic increase; and (D) CHO-Lec2 cells showed an increase in esterase activity comparable to the 





Figure 4.7. Time course of ManNAc analog induced changes and the effect of azido-labeled analogs on 
esterase activity.  (A) Structures of Bu4ManNAz and 1,3,4-O-Bu3ManAz, which (B) elicited an increase in 
esterase activity after 24 and 48 h of incubation of LS174T cells with the respective analogs. (C )Western 
blotting of proteins pulled down by click chemistry shows incorporation of SiaAz into CES2 in 1,3,4-O-







Table 4.1. In silico prediction of esterase N-glycosylation 
Name Accession 
Number 










































CEL AAA51973 1 210 9/9 ++ 
ESD AAC99788 NONE N/A N/A N/A 
CES1 AAI10339 1 79 7/9 + 
CES2 AAH32095 1 175 9/9 ++ 
CES3 ACD11491 1 105 6/9 + 























Table 4.2. Synopsis of CHO cell line experiments 
Cell line  Deficiency  Esterase 
activity  
Possible explanation  
K1  - Lack asparagine-linked 
glycosylation homolog ALG13 
which heterodimerizes with 
ALG14 to catalyze the second 
step in N-linked 
glycosylation(52) 
- Lack ST6Gal 
sialyltransferase responsible 
for formation of α-2,6-linked 
sialic acid terminal bonds (53)  
No 
increase  
- Absence of ALG 13 
could lead to N-
glycosylation deficiencies 
in some of the esterases  
- Formation of α-2,6 sialic 
acid terminal bonds plays 
an important role in the 
changes in esterase 
acitivity  
CHO-5  - Lack β4-Galactosyl 
transferase-6 essential for 
galactosylation of N-
glycans(54) 
- This may reduce N-glycan 






- Reduced N-glycan 
capacity for addition of 
terminal sialic acid 
reduces the  increase in 
esterase activity  
Lec2  - Defective CMP-sialic acid 
transporters required to 
transport sialic acid into the 
Golgi complex(55) 
Increase  - Increase in cytoplasm 
sialic acid concentration 
makes up  for the 







1. Hatfield, M.J.; Potter, P.M. Carboxylesterase inhibitors. Expert. Opin. Ther. Pat.  
2011,   21, 1159-1171. 
2. Pindel, E.V.; Kedishvili, N.Y.; Abraham, T.L.; Brzezinski, M.R.; Zhang, J.; Dean, 
R.A.; Bosron, W.F. Purification and cloning of a broad substrate specificity human liver 
carboxylesterase that catalyzes the hydrolysis of cocaine and heroin. J. Biol. Chem.  
1997,   272, 14769-14775. 
3. Gao, D.; Narasimhan, D.L.; Macdonald, J.; Brim, R.; Ko, M.C.; Landry, D.W.; 
Woods, J.H.; Sunahara, R.K.; Zhan, C.G. Thermostable variants of cocaine esterase for 
long-time protection against cocaine toxicity. Mol Pharmacol  2009,   75, 318-323. 
4. Lavis, L.D. Ester bonds in prodrugs. ACS Chem. Biol.  2008,   3, 203-206. 
5. Tsuji, T.; Kaneda, N.; Kado, K.; Yokokura, T.; Yoshimoto, T.; Tsuru, D. CPT-11 
converting enzyme from rat serum: purification and some properties. J Pharmacobiodyn  
1991,   14, 341-349. 
6. Jansen, W.J.; Zwart, B.; Hulscher, S.T.; Giaccone, G.; Pinedo, H.M.; Boven, E. 
CPT-11 in human colon-cancer cell lines and xenografts: characterization of cellular 
sensitivity determinants. Int. J. Cancer  1997,   70, 335-340. 
7. Zhu, H.-J.; Patrick, K.S.; Yuan, H.-J.; Wang, J.-S.; Donovan, J.L.; DeVane, C.L.; 
Malcolm, R.; Johnson, J.A.; Youngblood, G.L.; Sweet, D.H.; Langaee, T.Y.; Markowitz, 
J.S. Two CES1 gene mutations lead to dysfunctional carboxylesterase 1 activity in man: 




8. Oertel, J.; Hagner, G.; Kastner, M.; Huhn, D. The relevance of a-naphthyl acetate 
esterases to various monocyte functions. Br J Heamatol 1985,   61, 717-726. 
9. Burkhart, D.J.; Barthel, B.L.; Post, G.C.; Kalet, B.T.; Nafie, J.W.; Shoemaker, 
R.K.; Koch, T.H. Design, synthesis, and preliminary evaluation of doxazolidine 
carbamates as prodrugs activated by carboxylesterases. J. Med. Chem.  2006,   49, 7002-
7012. 
10. Weikert, T.; Ebert, C.; Rasched, I.; Layer, P.G. Novel inactive and distinctively 
glycosylated forms of butyrylcholinesterase from chicken serum. J. Neurochem.  1994,   
63, 318-325. 
11. Saez-Valero, J.; Barquero, M.; Marcos, A.; McLean, C.A.; Small, D.H. Altered 
glycosylation of acetylcholinesterase in lumbar cerebrospinal fluid of patients with 
Alzheimer's disease. J. Neurol. Neurosurg. Psych.  2000,   69, 664-667. 
12. Kolarich, D.; Weber, A.; Pabst, M.; Stadlmann, J.; Teschner, W.; Ehrlich, H.; 
Schwarz, H.P.; Altmann, F. Glycoproteomic characterization of butyrylcholinesterase 
from human plasma. Proteomics  2008,   8, 254-263. 
13. Meutermans, W.; Le, G.T.; Becker, B. Carbohydrates as scaffolds in drug 
discovery. ChemMedChem  2006,   1, 1164-1194. 
14. Elmouelhi, N.; Aich, U.; Paruchuri, V.D.P.; Meledeo, M.A.; Campbell, C.T.; 
Wang, J.J.; Srinivas, R.; Khanna, H.S.; Yarema, K.J. Hexosamine template. A platform 
for modulating gene expression and for sugar-based drug discovery. J. Med. Chem.  




15. Wang, Z.; Du, J.; Che, P.-L.; Meledeo, M.A.; Yarema, K.J. Hexosamine analogs: 
from metabolic glycoengineering to drug discovery. Curr. Opin. Chem. Biol.  2009,   13, 
565-572. 
16. Dube, D.H.; Bertozzi, C.R. Metabolic oligosaccharide engineering as a tool for 
glycobiology. Curr. Opin. Chem. Biol.  2003,   7, 616-625. 
17. Campbell, C.T.; Sampathkumar, S.-G.; Weier, C.; Yarema, K.J. Metabolic 
oligosaccharide engineering: perspectives, applications, and future directions. Mol. 
Biosys.  2007,   3, 187-194. 
18. Kayser, H.; Zeitler, R.; Kannicht, C.; Grunow, D.; Nuck, R.; Reutter, W. 
Biosynthesis of a nonphysiological sialic acid in different rat organs, using N-propanoyl-
D-hexosamines as precursors. J. Biol. Chem.  1992,   267, 16934-16938. 
19. Du, J.; Meledeo, M.A.; Wang, Z.; Khanna, H.S.; Paruchuri, V.D.P.; Yarema, K.J. 
Metabolic glycoengineering: sialic acid and beyond. Glycobiology  2009,   19, 1382-
1401. 
20. Sarkar, A.K.; Fritz, T.A.; Taylor, W.H.; Esko, J.D. Disaccharide uptake and 
priming in animal cells: inhibition of sialyl Lewis X by acetylated Gal b1,4GalcNAc b-
onaphthalenemethanol. Proc. Natl. Acad. Sci. U. S. A.  1995,   92, 3323-3327. 
21. Jones, M.B.; Teng, H.; Rhee, J.K.; Baskaran, G.; Lahar, N.; Yarema, K.J. 
Characterization of the cellular uptake and metabolic conversion of acetylated N-





22. Kim, E.J.; Sampathkumar, S.-G.; Jones, M.B.; Rhee, J.K.; Baskaran, G.; Yarema, 
K.J. Characterization of the metabolic flux and apoptotic effects of O-hydroxyl- and N-
acetylmannosamine (ManNAc) analogs in Jurkat (human T-lymphoma-derived) cells. J. 
Biol. Chem.  2004,   279, 18342-18352. 
23. Sampathkumar, S.-G.; Jones, M.B.; Meledeo, M.A.; Campbell, C.T.; Choi, S.S.; 
Hida, K.; Gomutputra, P.; Sheh, A.; Gilmartin, T.; Head, S.R.; Yarema, K.J. Targeting 
glycosylation pathways and the cell cycle: sugar- dependent activity of butyrate-
carbohydrate cancer prodrugs. Chem. Biol.  2006,   13, 1265-1275. 
24. Mathew, M.P.; Tan, E.; Shah, S.; Bhattacharya, R.; Meledeo, M.A.; Huang, J.; 
Espinoza, F.A.; Yarema, K.J. Extracellular and intracellular esterase processing of 
SCFA-hexosamine analogs: implications for metabolic glycoengineering and drug 
delivery. Bioorg. Med. Chem. Lett.  2012,   22, 6929-6933. 
25. Almaraz, R.T.; Tian, Y.; Bhattarcharya, R.; Tan, E.; Chen, S.-H.; Dallas, M.R.; 
Chen, L.; Zhang, Z.; Zhang, H.; Konstantopoulos, K.; Yarema, K.J. Metabolic flux 
increases glycoprotein sialylation: implications for cell adhesion and cancer metastasis. 
Mol. Cell. Proteomics  2012,   10.1074/mcp.M1112.017558  
26. Fukami, T.; Yokoi, T. The emerging role of human esterases. Drug Metab. 
Pharmacokinet.  2012,   27, 466-477. 
27. Fleming, C.D.; Bencharit, S.; Edwards, C.C.; Hyatt, J.L.; Tsurkan, L.; Bai, F.; 
Fraga, C.; Morton, C.L.; Howard-Williams, E.L.; Potter, P.M.; Redinbo, M.R. Structural 
insights into drug processing by human carboxylesterase 1: Tamoxifen, mevastatin, and 




28. Bencharit, S.; Morton, C.L.; Xue, Y.; Potter, P.M.; Redinbo, M.R. Structural basis 
of heroin and cocaine metabolism by a promiscuous human drug-processing enzyme. 
Nat. Struct. Biol.  2003,   10, 349-356. 
29. Aich, U.; Campbell, C.T.; Elmouelhi, N.; Weier, C.A.; Sampathkumar, S.G.; 
Choi, S.S.; Yarema, K.J. Regioisomeric SCFA attachment to hexosamines separates 
metabolic flux from cytotoxicity and MUC1 suppression. ACS Chem. Biol.  2008,   3, 
230-240. 
30. Almaraz, R.T.; Aich, U.; Khanna, H.S.; Tan, E.; Bhattacharya, R.; Shah, S.; 
Yarema, K.J. Metabolic oligosaccharide engineering with N-acyl functionalized ManNAc 
analogues: cytotoxicity, metabolic flux, and glycan-display considerations. Biotechnol. 
Bioeng.  2012,   109, 992-1006. 
31. Jourdian, G.W.; Dean, L.; Roseman, S. The sialic acids. XI. A periodate-
resorcinol method for the quantitative estimation of free sialic acids and their glycosides. 
J. Biol. Chem.  1971,   246, 430-435. 
32. Yarema, K.J.; Goon, S.; Bertozzi, C.R. Metabolic selection of glycosylation 
defects in human cells. Nat. Biotechnol.  2001,   19, 553-558. 
33. Kroetz, D.L.; McBride, O.W.; Gonzalez, F.J. Glycosylation-dependent activity of 
baculovirus-expressed human liver carboxylesterases: cDNA cloning and 
characterization of two highly similar enzyme forms. Biochemistry  1993,   32, 11606-
11617. 
34. Lamego, J.; Cunha, B.; Peixoto, C.; Sousa, M.F.; Alves, P.M.; Simplício, A.L.; 




new insights into enzyme oligomerization and activity. Appl. Microbiol. Biotechnol.  
2013,   97, 1161-1173. 
35. Werz, D.B.; Ranzinger, R.; Herget, S.; Adibekian, A.; Von der Lieth, C.W.; 
Seeberger, P.H. Exploring the structural diversity of mammalian carbohydrates 
("glycospace") by statistical databank analysis. ACS Chem. Biol.  2007,   2, 685-691. 
36. Granell, A.E.; Palter, K.B.; Akan, I.; Aich, U.; Yarema, K.J.; Betenbaugh, M.J.; 
Thornhill, W.B.; Recio-Pinto, E. DmSAS is required for sialic acid biosynthesis in 
cultured Drosophila third instar larvae CNS neurons. ACS Chem. Biol.  2011,   6, 1287-
1295. 
37. Tiemeyer, M.; Selleck, S.B.; Esko, J.D. Chapter 24. Arthropoda. Cold Spring 
Harbor (NY): Cold Spring Harbor Laboratory Press; 2009. 
38. Bencharit, S.; Morton, C.L.; Hyatt, J.L.; Kuhn, P.; Danks, M.K.; Potter, P.M.; 
Redinbo, M.R. Crystal structure of human carboxylesterase 1 complexed with the 
Alzheimer's drug tacrine. Chem. Biol.  2003,   10, 341-349. 
39. Imai, T. Human carboxylesterase isozymes: catalytic properties and rational drug 
design. Drug Metab. Pharmacokinet.  2006,   21, 173-185. 
40. Markey, G.M. Carboxylesterase 1 (Ces1): from monocyte marker to major player. 
J. Clin. Pathol.  2011,   64, 107-109. 
41. Sanghani, S.P.; Sanghani, P.C.; Schiel, M.A.; Bosron, W.F. Human 





42. Hori, T.; Hosokawa, M. DNA methylation and its involvement in 
carboxylesterase 1A1 (CES1A1) gene expression. Xenobiotica  2010,   40, 119-128. 
43. Dennis, J.W.; Nabi, I.R.; Demetriou, M. Metabolism, cell surface organization, 
and disease. Cell  2009,   139, 1229-1241. 
44. Luchansky, S.J.; Yarema, K.J.; Takahashi, S.; Bertozzi, C.R. GlcNAc 2-
epimerase can serve a catabolic role in sialic acid metabolism. J. Biol. Chem.  2003,   
278, 8036-8042. 
45. Yarema, K.J.; Mahal, L.K.; Bruehl, R.E.; Rodriguez, E.C.; Bertozzi, C.R. 
Metabolic delivery of ketone groups to sialic acid residues.  Application to cell surface 
glycoform engineering. J. Biol. Chem.  1998,   273, 31168-31179. 
46. Tian, Y.; Almaraz, R.T.; Choi, C.H.; Li, Q.K.; Saeui, C.; Li, D.; Shah, P.; 
Bhattacharya, R.; Yarema, K.J.; Zhang, H. Identification of sialylated glycoproteins from 
metabolically oligosaccharide engineered pancreatic cells. Clin Proteomics  2015,   12, 
doi: 10.1186/s12014-12015-19083-12018. 
47. Eisenberg, I.; Avidan, N.; Potikha, T.; Hochner, H.; Chen, M.; Olender, T.; 
Barash, M.; Shemesh, M.; Sadeh, M.; Grabov-Nardin, G.; Shmilevich, I.; Friedmann, A.; 
Karpati, G.; Bradley, W.G.; Baumbach, L.; Lancet, D.; Ben Asher, E.; Beckmann, J.S.; 
Argov, Z.; Mitrani-Rosenbaum, S. The UDP-N-acetylglucosamine 2-epimerase/N-
acetylmannosamine kinase gene is mutated in recessive hereditary inclusion body 
myopathy. Nat. Genet.  2001,   29, 83-87. 
48. Malicdan, M.C.V.; Noguchi, S.; Tokutomi, T.; Goto, Y.-i.; Nonaka, I.; Hayashi, 




efficiently rescues muscle phenotype and biochemical defects in mouse model of sialic 
acid-deficient myopathy. J. Biol. Chem.  2012,   287, 2689-2705. 
49. Greig, N.H.; Lahiri, D.K.; Sambamurti, K. Butyrylcholinesterase: an important 
new target in Alzheimer's disease therapy. Int Psychogeriatr  2002,   14 (Suppl 1), 77-91. 
50. Nordberg, A.; Ballard, C.; Bullock, R.; Darreh-Shori, T.; Somogyi, M. A review 
of butyrylcholinesterase as a therapeutic target in the treatment of Alzheimer's disease. 
Prim Care Companion CNS Disord  2013,   15, pii: PCC.12r01412. 
51. Ceroni, A.; Maass, K.; Geyer, H.; Geyer, R.; Dell, A.; Haslam, S.M. 
GlycoWorkbench: a tool for the computer-assisted annotation of mass spectra of glycans. 
J. Proteome Res.  2008,   7, 1650-1659. 
52. Xu, X.; Nagarajan, H.; Lewis, N.E.; Pan, S.; Cai, Z.; Liu, X.; Chen, W.; Xie, M.; 
Wang, W.; Hammond, S. The genomic sequence of the chinese hamster ovary (CHO)-K1 
cell line. Nat. Biotechnol.  2011,   29, 735-741. 
53. Gao, X.D.; Tachikawa, H.; Sato, T.; Jigami, Y.; Dean, N.A. Alg14 recruits Alg13 
to the cytoplasmic face of the endoplasmic reticulum to form a novel bipartite UDP-N-
acetylglucosamine transferase required for the second step of N-linked glycosylation. J. 
Biol. Chem.  2005,   280, 36254-36362. 
54. Lee, J.H.; Sundaram, S.; Shaper, N.L.; Raju, S.; Stanley, P. Chinese hamster 
ovary (CHO) cells may express six β4-Galactosyltransferases (β4GalTs). J. Biol. Chem.  
2001,   276, 13924-13934. 
55. Eckhardt, M.; Gotza, B.; Gerardy-Schahn, R. Mutants of the CMP-sialic acid 





METABOLIC GLYCOENGINEERING SENSITIZES DRUG-
RESISTANT PANCREATIC CANCER CELLS TO 
TYROSINE KINASE INHIBITORS ERLOTINIB AND 
GEFITINIB 
ABSTRACT 
Metastatic human pancreatic cancer cells (the SW1990 line) that are resistant to 
the EGFR-targeting tyrosine kinase inhibitor drugs (TKI) erlotinib and gefitinib were 
treated with 1,3,4-O-Bu3ManNAc, a “metabolic glycoengineering” drug candidate that 
increased sialylation by ~2-fold. Consistent with genetic methods previously used to 
increase EGFR sialylation, this small molecule reduced EGF binding, EGFR 
transphosporylation, and downstream STAT activation.  Significantly, co-treatment with 
both the sugar pharmacophore and the existing TKI drugs resulted in strong synergy, in 
essence re-sensitizing the SW1990 cells to these drugs. Finally, 1,3,4-O-Bu3ManNAz, 
which is the azido-modified counterpart to 1,3,4-O-Bu3ManNAc, provided a similar 
benefit thereby establishing a broad-based foundation to extend a “metabolic 
glycoengineering” approach to clinical applications. 
 
This chapter was originally published as Mathew, M. P., Tan, E., Saeui, C. T., Bovonratwet, P., Liu, L., 
Bhattacharya, R., & Yarema, K. J. (2015). Metabolic glycoengineering sensitizes drug-resistant 
pancreatic cancer cells to tyrosine kinase inhibitors erlotinib and gefitinib. Bioorganic & medicinal 





Tumor-associated carbohydrate antigens (TACAs) have been associated with 
cancer for decades (1-4) and abnormal glycosylation is now accepted to be a universal 
feature of cancer (5).  Despite the many roles glycosylation has been discovered to play 
in cancer progression and metastasis (6-9), progress in exploiting this knowledge in a 
clinical setting has been agonizingly slow (8, 10). The epidermal growth factor receptor 
(EGFR) exemplifies the “sweet and sour” (10) or “bittersweet” (8) nature of 
glycosylation in cancer. On one hand, several papers over the past ~15 years have 
reported that modulation of EGFR’s glycosylation status – in particular changes to fucose 
and sialic acid – control this receptor’s ability to drive cancer progression.  For example, 
a recent report showed that increased sialylation or fucosylation of EGFR suppressed 
dimerization, inhibited subsequent phosphorylation, and dampened activation of 
downstream signaling in lung cancer cells (11). On the other hand, although these 
responses would be expected to slow cancer cell growth, the methods used to 
demonstrate these features in cell culture experiments, such as enzymatic removal of 
sugars or genetic over-expression of glycosyltransferases, are not easily translated to 
animal testing or to a human clinical setting thereby illustrating the general difficulties in 
developing carbohydrate-based cancer therapies.   
In this chapter I overcome a hurdle towards clinical exploitation of the 
glycosylation status of EGFR by using small molecule “metabolic glycoengineering” 
sugar analogs to increase the sialylation of this receptor and reduce its activity in ways 
that were previously only accomplished genetically (11, 12). Metabolic glycoengineering 




versatile technique used to change patterns of glycosylation by altering the availability or 
chemical composition of biosynthetic precursors of glycans (16, 17). For example, short 
chain fatty acid (SCFA)-modified ManNAc analogs can efficiently enhance metabolic 
flux through the sialic acid biosynthetic pathway (18, 19) and increase cell surface 
sialylation (20).  The ester-linked SCFA moieties, which are usually acetate (21-23) or n-
butyrate (19, 24), increase cellular uptake by three orders of magnitude or more and upon 
entering a cell, intracellular esterases rapidly remove the SCFA groups (25), regenerating 
the core sugar that enters the targeted biosynthetic pathway.  This strategy positions 
SCFA-modified sugars as viable drug candidates, as evidenced by the recent use of 
Ac4ManNAc to reverse the symptoms of hereditary inclusion body myopathy in an 
animal model of this disease (26).  
One drawback of SCFA-conjugated monosaccharide drug candidates is 
cytotoxicity that, while not severe, can hinder metabolic incorporation into cell surface 
glycans (18, 19, 27). Our laboratory has addressed this problem by exploiting structure 
activity relationships (SARs) that attribute analog-mediated cytotoxicity to the presence 
of a SCFA group at the C6 position of a hexosamine (28, 29). This discovery enabled the 
development of tributanoylated sugars such as 1,3,4-O-Bu3ManNAc (Figure 5.1) that 
achieve high flux into the sialic acid pathway at low analog concentrations compared to 
the widely used peracylated compounds (e.g., Ac4ManNAc, also shown in Figure 5.1) 
(20).  Of particular relevance to our efforts to develop glycosylation-based therapies for 
chemotherapy-resistant pancreatic cancer, we found that EGFR in SW1990 cells treated 




mass spectrometry-based “glycosite” (30) and glycan analysis methods similar to those 
already reported (31, 32).   
 
5.2 MATERIALS AND METHODS 
5.2.1 Cell Culture and Incubation with Sugar Analogs 
SW1990 (ATCC
®
 CRL-2172) cells were grown in Dulbecco's Modified Eagle 
Medium (DMEM) supplemented 10 % with heat-inactivated fetal bovine serum (FBS) 
and 1.0 % of 100x pen/strep antibiotic solution (Invitrogen).  Cells were maintained at 37 
°C in a humidified atmosphere containing 5% CO2.  For treatment of cells, cells typically 
were plated in 6-well tissue culture plates in 2.0 mL of culture media at a density of 
300,000 cells/well.  Sugar analogs, either 1,3,4-O-Bu3ManNAc or 1,3,4-O-Bu3ManNAz 
were synthesized and characterized as previously described (20, 28) and stored 
lyophilized at -80 °C. Stock solutions (100 mM) were made in ethanol (EtOH) and the 
compounds were added to each well to achieve the desired analog concentrations; the 
identical volume of ETOH (always less than 10 
in ethanol (EtOH) and the compounds were added to each well to achieve the desired 
analog concentrations; the st concentration of analog. Cells were typically incubated for 
48 h with the sugar analogs; in many experiments (as indicated below) the first 24 h of 
incubation was carried out in complete media and the cells were serum starved for the 
final 24 h before analysis following published protocols for monitoring EGFR 





5.2.2 EGF Saturation Binding Assays 
Cells were incubated for 48 h with 1,3,4-O-Bu3ManNAc with serum starvation 
over the last 24 h.  The cells were washed with PBS, treated with enzyme free cell 
dissociation buffer (Life Technologies) until they detached from the culture plate, 
collected, and counted and cell numbers were normalized using the Beckman Z2 cell 
coulter counter.  Cells were then washed twice in Live Cell Imaging Solution (Life 
Technologies) supplemented with 1.0% bovine serum albumin (BSA) and 20 mM 
glucose. Cells were then incubated at room temperature for 2 h with 2 µg/mL of Alexa 
Fluor 488-linked EGF (Life Technologies).  Cells were washed three times in Live Cell 
Imaging Solution and analyzed using flowcytometry with an Accuri C6 Flow cytometer.  
5.2.3 Immunofluorescence 
Cells were analyzed by fluorescence microscopy after incubation with analogs for 48 
h including serum-starvation over the last 24 h after which they washed with phosphate 
buffered saline (PBS) and then incubated with 10 ng/mL recombinant human EGF 
(Peprotech AF-100-15) in PBS for 2.0 min to activate EGFR signaling from basal levels 
(11). Cells were then fixed, permeabilized, blocked and incubated with human specific 
anti-phospho-EGFR (Cell Signaling) primary antibody for 1.0 h at room temperature.  
After incubation with the primary antibody, cells were washed and incubated with FITC-
linked anti-rabbit (Sigma-Aldrich) secondary antibody for 1.0 h at room temperature. 
Cells were then washed and incubated with 4,6-diamidino-2-phenylindole (DAPI) for 10 
min to stain the nuclei of the cells. After incubation, cells were washed and images were 
taken using an excitation wavelength of 495 nm and an emission wavelength of 519 nm 




5.2.4 Western Blot Analysis 
Proteins obtained from SW1990 cells were analyzed by western blots after the 
cells were incubated with 1,3,4-O-Bu3ManNAc for 48 h including, as described above, 
serum starvation for the last 24 h and exposure to 10 ng/mL recombinant human EGF 
(Peprotech AF-100-15) in PBS for 2.0 min.  Proteins were collected and were immuno-
detected using the following commercial antibodies: anti-phospho-EGFR (Cell 
Signaling), anti-EGFR (Cell Signaling), anti-phospho-STAT3 (Cell Signaling), anti-
PBS for 2.0 min.  Proteins were collected and were imy (Cell Signaling). Protein bands 
were quantified using the ImageJ software. 
5.2.5 Growth Inhibition Assays to Determine Drug Synergy 
Cells were incubated with 1,3,4-O-Bu3ManNAc or 1,3,4,-O-Bu3ManNAz for 48 
h, typically at low concentrations (e.g., 25 or 50 
concentrations (e.g., 25 or 50  Signaling). Protein bands were quantified using the ImageJ 
software.Cell Signaling), anti-EGFR (Cell Signaling), anti-phospho the wells.  After an 
additional 72 h incubation period the cells were washed, trypsinized, and counted using a 
Beckman Z2 cell coulter counter.  
5.2.6 Statistical Analysis 
Data was expressed as means ± standard error (SEM). Statistical significance was 
determined using one way ANOVA with a dunnett’s post-test to compare means of 
different samples with the control. The null hypothesis was rejected in cases where p-





5.3 RESULTS AND DISCUSSION 
Based on the precedent from at least two groups who used genetic methods to 
increase EGFR sialylation (11, 12), I reasoned that 1,3,4-O-Bu3ManNAc would likewise 
reduce EGFR activity.  This hypothesis was experimentally confirmed by the 
experiments shown in Figure 5.2 where I first measured saturation binding to 
fluorescently-labeled EGF and showed a measurable decrease in available cell surface 
receptors for EGF (Figure 5.2A).  In turn, immunofluorescence assays showed that 
analog treatment led to a decrease in EGFR phosphorylation (Figure 2B with additional 
images provided in Supplemental Figure S5.1), which was confirmed by western blots 
that also showed a decrease in phospho-EGFR (p-EGFR) in cells treated with 1,3,4-O-
Bu3ManNAc while the total amount of EGFR was unchanged (Figure 5.2C).   
Although the changes in EGFR phosphorylation were relatively modest in 1,3,4-
O-Bu3ManNAc treated cells, small differences in starting conditions for receptors that 
initiate phosphorylation cascades typically are amplified downstream. To test whether 
this characteristic response of signaling pathways applied to 1,3,4-O-Bu3ManNAc-driven 
changes to p-EGFR, phospho-STAT3 (p-STAT3) which is a “hallmark” downstream 
element of EGFR-initiated signaling, was monitored by western blot analysis. This 
experiment confirmed that the predicted enhanced response did occur for STAT3, with a 
stronger dose-dependent decrease in p-STAT3 levels observed in 1,3,4-O-Bu3ManNAc-
treated SW1990 cells as shown by western blots (Figure 5.3A) and quantification by 
Image J software (Figure 5.3B).  The series of experiments beginning with reduction of 
EGF binding, progressing to show decreased EGFR phosphorylation, and culminating 




O-Bu3ManNAc indicate that even modest changes in behavior of surface receptors due to 
altered glycosylation have potential therapeutic benefit. To gain a sense whether these 
biochemical markers of signaling pathway activation had an impact on actual cell 
behavior, we monitored cell proliferation and found that, given sufficiently high levels of 
1,3,4-O-Bu3ManNAc, SW1990 cell proliferation decreased (Figure 5.3C).  
Despite the decreased cell proliferation observed in 1,3,4-O-Bu3ManNAc treated 
cells, the high concentrations required to substantially inhibit growth (e.g., > 250 µM) 
may be difficult to achieve in vivo; therefore, the prospects for using 1,3,4-O-
Bu3ManNAc as a “stand alone” drug for inhibiting EGFR in TKI resistant cell lines are 
uncertain. The mechanism by which increased sialylation impacts EGFR, however – 
which is reported to be decreased dimerization and a concomitant reduction in 
transphosporylation (11) – is orthogonal to other mechanisms by which cancer cells 
become resistant to TKIs such as single point mutations that affect the binding of these 
drugs to EGFR (33) or the constitutive activation of ERK signaling that can circumvent 
EGFR inhibition (34).  Therefore regardless of current uncertainties in the exact 
mechanism by which 1,3,4-O-Bu3ManNAc modulates EGFR activation and signaling, we 
reasoned that co-administration of this drug candidate with TKIs such as erlotinib or 
gefitinib would have an synergistic effect and, in a best case scenario, re-sensitize drug-




To evaluate synergy between 1,3,4-O-Bu3ManNAc and TKIs, SW1990 cells were 
incubated with 0, 25, and 50 µM of 1,3,4-O-Bu3ManNAc and then co-treated with a 
range of concentrations of erlotinib or gefitinib.  These levels of 1,3,4-O-Bu3ManNAc are 
sufficient to increase sialylation (20) and diminish phosphorylation of STAT (Figure 
5.3B) but result in virtually no growth inhibition when the sugar analog is used alone 
(Figure 5.3C).   As shown in Figure 5.4A neither erlotinib or gefinitib alone were 
effective at slowing proliferation SW1990 cells at low nanomolar concentrations but 
when used in combination with 1,3,4-O-Bu3ManNAc the sensitivity to these drugs 
dramatically increased.  Indeed, reduction in cell growth of 40 to 50% (which are levels 
associated with clinically effective response) occurred in the tens of nanomolar range for 
both erlotinib and gefitinib when the cells were co-treated with 50 µM of 1,3,4-O-
Bu3ManNAc; this level of sensitivity to these TKIs are comparable to that observed in 
drug-responsive pancreatic cancer lines (35).  In essence, the sugar analog reversed the 
drug resistance of this cell line. 
The Combination Index (CI) (36) was used to more rigorously quantify synergy 
between ManNAc analogs and existing drugs based on the following relationship: 
   
  
     
  
  





To calculate the CI, D1 (e.g., 1,3,4-O-Bu3ManNAc) and D2 (e.g., erlotinib or gefitnib) 
represent the concentrations of each drug in combination with each other that required to 
inhibit cell growth by a given amount (x%) and (Dx)1 and (Dx)2 are the concentrations of 
each drug required to cause x% inhibition when the drugs are used individually. A CI = 1 
indicates an additive effect, a CI > 1 indicates an antagonistic effect, and a CI < 1 
indicates a synergistic effect (36). Figure 5.4B plots the CI measured for each analog-
drug combination (using data from Figure 5.4A for the TKI drugs when used alone and 
Figure 5.3C for 1,3,4-O-Bu3ManNAc alone).  Strong synergy was observed between 
1,3,4-O-Bu3ManNAc and both erlotinib and gefitinib with combination indexes ranging 
from 0.7 to as low as 0.23.  It is noteworthy that stronger synergy (e.g., lower CI values) 
was observed for 25 µM of 1,3,4-O-Bu3ManNAc compared to 50 µM, indicating that the 
beneficial effects of this sugar analog “kick in” at low concentrations. Overall, these 
results position sugar analogs such as 1,3,4-O-Bu3ManNAc as valuable agents for 
sensitizing drug-resistant pancreatic cancer to existing therapies that target EGFR.   
A final set of experiments investigated whether the azide-modified ManNAc 
analog 1,3,4-O-Bu3ManNAz (shown in Figure 5.1), which is incorporated into cell 
surface glycans as the non-natural “Sia5Az” form of sialic acid (37), also provides 
synergy with EGFR-targeting TKI drugs.  The use of a sialic acid precursor with a non-
natural acyl group was of interest for two reasons; one was based on a previous report 
that this class of compounds could sensitize cancer cells towards chemotherapy and 
radiation treatment (38). Secondly, azido-modified sugar analogs are capable of labeling 
cells through click chemistry (20, 37), thereby opening new possibilities of not only 




provide a means to direct additional diagnostic or therapeutic agents to sialylated glycans 
overexpressed in cancer (39, 40). In the current experiments, azido-modified 1,3,4-O-
Bu3ManNAz was more cytotoxic on its own (Figure 5.4C) compared to 1,3,4-O-
Bu3ManNAc, therefore lower concentrations of 12.5 and 25 µM were used to evaluate 
synergy (Figure 5.4D).  Even at these low levels of 1,3,4-O-Bu3ManNAz, strong 
incorporation into cellular glycans occurs (20) and synergy with erlotinib was observed 
with CI values ranging from 0.68 to as low as 0.34 (Figure 5.4E).   
In summary, this chapter describes two important findings, the first is that the 
manipulation of EGFR glycosylation in ways that reduce signaling and dampen endpoints 
related to cancer progression can now be done with pharmacologically-relevant small 
molecules rather than the genetic approaches previously reported.  The second finding is 
that treatment of TKI-resistant pancreatic cancer cells with the sugar analogs can restore 
sensitivity to erlotinib and gefitinib.  These results provide a scientific foundation for 
further investigation beyond the scope of this chapter; for example it is not known how 
widely the drug synergy will apply across cell lines and tissue types and a detailed 
accounting of the mechanism by which synergy is achieved remains to be described.   
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5.5 FIGURES  
Figure 5.1. ManNAc and analogs used for metabolic glycoengineering pancreatic cancer cells for 
increased sensitivity to EGFR-targeting TKI drugs.  (A) Natural ManNAc. (B) Fully acetylated ManNAc, 





Figure 5.2.  1,3,4-O-Bu3ManNAc decreases EGFR phosphorylation. (A) Saturation binding where cells 
were incubated with Alexa Fluor® 488 labeled EGF for one hour at room temperature and then measured 
using flow cytometry shows a decrease in available surface bound EGFR.  At least 3 biological replicates 
were carried out for each experiment with data expressed as mean ± standard error mean (SEM). (B) 
Representative images of immunofluorescence assays (additional images are provided in Supplemental 
Figure S5.1) where cells were incubated with EGF for 2.0 min, fixed and stained with anti-p-EGFR, FITC 
labeled anti-rabbit antibody, and stained with DAPI confirm that EGFR phosphorylation decreases with 
analog treatment. (C) Western blots of SW1990 pancreatic cancer cells treated with increasing levels of 
1,3,4-O-Bu3ManNAc showed a decrease in phosphorylated EGFR with no significant change in overall 





Figure 5.3. Downstream effects of 1,3,4-O-Bu3ManNAc treatment of SW1990 cells and reduced EGFR 
phosphorylation.  (A) Representative images of western blots of SW1990 cells treated with different 
concentrations of 1,3,4-O-Bu3ManNAc showed a significant decrease in phosphorylated STAT3 (as 
quantified by Image J analysis in Panel B). (C) Finally, 1,3,4-O-Bu3ManNAc reduced cell proliferation 
albeit at higher concentrations than where effects on EGFR-mediated signaling endpoints were observed.  
At least 3 biological replicates were carried out for each experiment with data expressed as mean ± 





Figure 5.4. Determination of synergy between glycosylation and EGFR-acting drugs.  (A) Growth 
inhibition of SW1990 cells treated with gefitinib or erlotonib in combination with 1,3,4-O-Bu3ManNAc. (B) 
The Combination Index (CI) for each analog-drug combination was determined and plotted against the 
percentage inhibition observed (x%), with both drugs showing strong synergy with the sugar analog.  At 
least 3 biological replicates were carried out for each experiment with data expressed as mean ± standard 
error mean (SEM) as depicted in Supplemental Figure S5.2. (C) Growth inhibition of SW1990 cells 
treated with 1,3,4-O-Bu3ManNAz. (D) Growth inhibition when erlotonib and 1,3,4-O-Bu3ManNAz were 
used in combination with the combination index provided in Panel (E). At least 3 biological replicates were 





Supplemental Figure S5.1: Representative images at 10 X magnification of immunofluorescence assays 
where cells were incubated with EGF for 2.0 min, fixed and stained with anti-p-EGFR, FITC labeled anti-
rabbit antibody, and DAPI confirm that EGFR phosphorylation decreased with sugar analog treatment. 
This figure shows additional “representative data” from 
immunofluorescence assays that demonstrate the ability of 1,3,4-O-Bu3ManNAc to reduce p-EGFR levels 





















Supplemental Figure S5.2: Details showing additional data obtained over low concentration ranges for 
the drug synergy experiments presented in Figure 5.4A. At least 3 biological replicates were carried out 
for each experiment with data expressed as mean ± standard error mean (SEM). This figure provides a 
more detailed depiction of low concentration ranges of the experiment used to determine drug synergy 
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INSIGHTS INTO THE SENSITIZATION AND TARGETING 
OF THE EPIDERMAL GROWTH FACTOR RECEPTOR 
(EGFR) IN SW1990 PANCREATIC CANCER CELLS BY 
METABOLIC FLUX_DRIVEN SIALYLATION 
 
ABSTRACT 
     We recently reported that advanced stage pancreatic cancer cells (the metastatic 
SW1990 line), which respond weakly to the EGFR-targeting tyrosine kinase inhibitors 
(TKIs) erlotinib and gefitinib can be resensitized to these drugs by treatment with 1,3,4-
O-Bu3ManNAc (Bioorg. Med. Chem. Lett. (2015) 25(6):1223-7). To gain insight into 
how increased sialylation experienced by many glycoproteins (including EGFR) in cells 
treated with this sugar inhibits this receptor and leads to synergy with TKI drugs, we took 
three approaches:  
First, we verified that 1,3,4-O-Bu3ManNAc treatment, a “high flux” ManNAc analog 
increases sialylation of EGFR, albeit to a lower extent than global sialylation, in human 
SW1990 pancreatic cancer cells. We then implemented a computational model that 
helped predict that this compound increased the internalization of EGFR consistent with 





Second, we experimentally verified these predictions by showing that EGFR was 
internalized at a faster rate in 1,3,4-O-Bu3ManNAc-treated cells and that a shift away 
from clathrin coated internalization to  NCM endocytosis did occur. 
Third, we evaluated down-stream targets of EGFR signaling and linked drug synergy 
between 1,3,4-O-Bu3ManNAc and existing TKI drugs to the bias away from clathrin-
coated endocytosis, which allows EGFR signaling to continue after internalization, 
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and Targeting of the Epidermal Growth Factor Receptor (EGFR) in Pancreatic Cancer Cells by 




6.1 INTRODUCTION  
In mammals, glycosylation is a ubiquitous co/post-translational modification of cell 
surface proteins and lipids that modulates the activities of these molecules in a myriad of 
ways that – despite decades of study – often continue to be poorly understood and 
sometimes turn out to be downright surprising.  An example of a such a result is the 
unexpected ability of 1,3,4-O-Bu3ManNAc, a “high flux” N-acetylmannosamine 
(ManNAc) analog that increases sialylation (1-4), to sensitize drug-resistant pancreatic 
cancer cells to tyrosine kinase inhibitors (TKIs) (5).   
To elaborate briefly, sialic acid has generally been regarded as a cancer-promoting 
sugar moiety, occurring in many tumor-associated carbohydrate antigens (TACAs) such 
as the sialylated Tn antigen (sTn), sialyl Lewis X (sLe
X
) and ganglioside GM3 (6, 7); in 
addition, in many molecular contexts the bulk chemical properties of sialic acid are anti-
adhesive and provide a pro-metastatic mechanism for cancer cells to detach from a 
primary tumor. Based on these factors, it is generally accepted that increased sialylation 
promotes cancer progression.  Accordingly, increased sialylation is thought to be counter-
productive in cancer therapy and this dogma has posed a conundrum for efforts to exploit 
metabolic oligosaccharide engineering (MOE (8, 9), also known as metabolic 
glycoengineering, MG or MGE (10), for which detailed background information is 
provided in the cited articles (11-14)) to treat cancer. To illustrate this point, MOE has 
potential to manipulate sialylated glycans in ways that have an anti-cancer impact by 
installing non-natural sialic acids in over-expressed TACAs for delivery of diagnostic 
(15, 16) or therapeutic agents (17) or even fluorinated sugars intended to have anti-




potential to promote cancer progression by increasing overall levels of sialylation and for 
this reason (and others beyond the scope of this discussion) MOE has made only paltry 
progress towards clinical adoption.   
Based on the widely held assumption that sialylation is synonymous with increased 
carcinogenicity, several recently-reported results to the contrary are provocative.  In 
particular, we recently reported that 1,3,4-O-Bu3ManNAc – a ManNAc “pro-drug” that is 
rapidly activated by esterases in cells to generate ManNAc (20) that promotes high levels 
of flux through the sialic acid biosynthetic pathway (2) and substantially increases cell 
surface sialylation in human cancer cells (3) – had only a modest (in fact almost 
negligible) impact on endpoints related to metastasis such as in vitro cell motility (3). 
One explanation for this result could be that once increased sialylation has occurred, any 
additional increase is not capable of further exacerbating cancer progression. Indeed, 
although increased sialylation is associated with many aspects of oncogenesis (21, 22), 
too large of an increase in sialic acid may actually be detrimental to cancer progression. 
This idea is consistent with descriptions of only “slightly increased” levels of sialic acid 
in some types of cancer (23) and feedback mechanisms that carefully titer metabolic flux 
into the sialic acid biosynthetic pathway (24, 25).  
The epidermal growth factor receptor (EGFR), an oncogene that has been linked to 
poor prognosis in pancreatic (and other) cancer (26-28), provides an example where over-
sialylation deters cancer progression. The glycosylation status of EGFR has been linked 
to changes in receptor activity as well as to overall cell behavior (29, 30).  For example, 




(31) and inhibition of N-glycosylation with tunicamycin sensitized human non-small lung 
cancer cells to erlotinib (32).  
Focusing on sialic acid, increased levels of this sugar resulting from genetic 
manipulation (e.g., over-expression of sialytransferases) have been reported to inhibit 
EGFR activity in lung (29, 33) and colon (34) cancer cells. Building on these findings, 
our group recently showed that a pharmacologically relevant “small molecule” approach 
using 1,3,4-O-Bu3ManNAc to increase sialylation could reproduce the biological effects 
of these genetic manipulations. In particular, this ManNAc analog sensitized drug-
resistant cancer cell lines to the tyrosine kinase inhibitors (TKIs) erlotinib and gefitinib 
that are currently used as cancer therapeutics (5) but are only modestly effective because 
the rapid gain of drug resistance in patients (35). Based on the clinical potential of this 
finding, in this paper I sought to better understand the impact of 1,3,4-O-Bu3ManNAc on 
EGFR signaling, gain insight into the underlying molecular mechanism, and further 
investigate the unusual synergy between TKIs and this sugar analog.  
 
6.2 MATERIALS AND METHODS 
6.2.1 Cell Culture and Incubation with Sugar Analogs.  
SW1990 (ATCC
®
 CRL-2172) cells were grown in Dulbecco's Modified Eagle Medium 
(DMEM) supplemented 10% with heat-inactivated fetal bovine serum (FBS) and 1.0% of 
100x pen/strep antibiotic solution (Invitrogen). Cells were maintained at 37°C in a 
humidified, 5% CO2-containing atmosphere. 1,3,4-O-Bu3ManNAc was synthesized and 




solutions (100 mM) were made in ethanol (EtOH).  For analog treatment, cells typically 
were plated in 6-well tissue culture plates in 2.0 mL of culture media at a density of 
300,000 cells/well and the appropriate volume of 1,3,4-O-Bu3ManNAc was added to 
each well to achieve the desired analog concentrations; the identical volume of ETOH 
(always less than 10 µL/mL) was added to each well in each experiment to ensure that all 
cells were exposed to the same amount of solvent as those treated with the highest 
concentration of analog. Cells were typically incubated for 48 h with the sugar analogs; 
in certain experiments (as indicated below) the first 24 h of incubation was carried out in 
complete media and the cells were serum starved for the final 24 h before analysis 
following published protocols for monitoring EGFR phosphorylation and activation [29). 
6.2.2 Western Blot Analysis.  
Proteins obtained from SW1990 cells were analyzed by western blots after the cells were 
incubated with 1,3,4-O-Bu3ManNAc, erlotinib or both for 48 h including, as described 
above, serum starvation for the last 24 h and exposure to 10 ng/mL recombinant human 
EGF (Peprotech AF-100-15) in PBS for 2.0 min, 30 min or 60 min.  Proteins were 
collected and were immuno-detected using the following commercial antibodies: anti-
phospho-EGFR (p-EGFR, Tyr1068 Cell Signaling #4267), anti-EGFR (D33B1, Cell 
Signaling, #4267), anti-STAT3 (STAT3, 79D7, Cell Signaling #4904), anti-phospho-
STAT3 (p-STAT3, Tyr705, Cell Signaling #9131), anti-phospho-AKT (p-Akt, Ser473 
(D9E) Cell Signaling #4060), anti-phospho-ERK1/2 (p-ERK1/2 Try202/204, Cell 
Signaling, #9101), anti-β-actin (Sigma-Aldrich) and HRP-linked anti-rabbit antibody 




necessary, blots were stripped with Gentle ReView Stripping Buffer (Amresco), 
reblocked and analyzed. 
6.2.3 EGFR Immunopurification and Characterization of Sialylation.  
Cells were incubated for 48 h with 100 µM 1,3,4-O-Bu3ManNAc, rinsed in ice cold PBS, 
collected using cell scrapers, and resuspended in 0.5 mL of ice cold cell lysis buffer (Cell 
Signaling). Samples were sonicated on ice three times for 5 s each and then samples were 
centrifuged for 10 min at 4 ⁰C at 14,000g. Protein from control and treated cells were 
collected from the supernatant, quantified using the Pierce 660 nm protein assay (Thermo 
Scientific); protein levels were then normalized to 1.0 mg/mL.  EGFR from control and 
treated samples was then immunopurified using Sepharose bead conjugated EGFR mAb 
(Cell Signaling) following the manufacturer’s protocol. After purification, the samples 
were divided in two with half of the samples boiled in loading buffer for 10 min and then 
analyzed for total EGFR protein levels by western blotting as described above. HRP-
linked SNA-1 Lectin (EY Laboratories) was also used to stain western blots of 
immunopurified EGFR to determine the levels of α2-6 linked sialic acid. Band intensities 
were quantified using ImageJ software and normalized to EGFR levels. 
6.2.4 Fluorescent Assisted Carbohydrate Electrophoresis (FACE).  
The other half of the immunopurified EGFR samples were digested with sialidase 
(P0722L, New England BioLabs), wherein 10 µL of immunopurified EGFR on 
sepaharose beads was incubated with 200 units of sialidase in a 100 µL reaction volume 
for 48 h at 37⁰C. After sialidase digestion, the samples were centrifuged at 14,000g and 
the amount of sialic acid released into the supernatants was determined by FACE 




were prepared and activated with 80% acetonitrile, 0.1% v/v trifluoroacetic acid (TFA) 
using three 1.0 mL washes and were then equilibrated with five 1.0 mL milli Q water 
washes under vacuum. The supernatants were then loaded onto the columns and the 
columns were washed five times with 1.0 mL of milliQ water under vaccum after which 
the released sialic acids were eluted under gravity using 1.0 mL of 25% acetonitrile, 0.1% 
v/v TFA. The samples were then lyophilized, resuspended in 150 µL of milli Q water, 
transferred into fresh 1.5 mL eppendorf tubes, and lyophilized again. These samples, 
along with sialic acid standards, were then labeled with 40 µL of a 6.25 mM 2-
aminoacridone (Carbosynth) solution in DMSO overnight at 37 ⁰C.  
A gel solution was prepared with 500 mL of 40% acrylamide (BioRad), 100 mL tris-
acetate (400 mM, pH 7.0), 370 mL milliQ water and 25 mL of glycerol. An aliquot of the 
gel solution (5 mL) was then mixed with 25 µL of 10% ammonium persulfate and 5 µL 
of TEMED (BioRad) and poured into preassembled casting plates with a 0.75 mm well 
comb. After 7.5 min the combs were removed and the gels were transferred into the gel 
apparatus (BioRad) and the apparatus was filled with 1X tris-borate EDTA (BioRad). 
The gel apparatus was then placed on ice for 2.0 h. An aliquot of each sample (2 µL) was 
then loaded onto the gel and the gel was run at 500 V for 40 min on ice. The gel was then 
transferred onto a visi-blue benchtop variable UV transilluminator and imaged. Band 
intensities were then quantified using ImageJ software and normalized to the EGFR 
levels measured in the western blots described above. 
6.2.5 Confocal Microscopy for Cell Surface EGFR Measurement.  
Cells were incubated for 48 h with 1,3,4-O-Bu3ManNAc with serum starvation over the 




10 min. Cells were then blocked with 5% bovine serum albumin (BSA) in PBS for 1.0 h. 
Cells were then incubated overnight at 4⁰C with Alexa Fluor 488-conjugated EGFR mAb 
(Cell Signaling). Nuclei were stained with DAPI. After three washes in PBS, the cells 
were imaged on Zeiss AxioObserver with 780-Quasar confocal module & FCS. Gross 
fluorescence was determined for Alexa Fluor 488-conjugated EGFR mAb and DAPI 
for each image using ImageJ software. The relative fluorescence of each 1,3,4-O-
Bu3ManNAc-treated sample was determined by normalizing Alexa Fluor 488-
conjugated EGFR mAb fluorescence to DAPI fluorescence and then normalizing to 
control samples not treated with analog. 
6.2.6 Fluorescent Recovery After Photobleaching (FRAP) Assays.  
Cells were incubated for 48 h with 1,3,4-O-Bu3ManNAc with serum starvation over the 
last 24 h. The cells were washed in Live Cell Imaging Solution (Life Technologies) 
supplemented with 1.0% bovine serum albumin (BSA) and 20 mM glucose and then 
incubated at 37°C with 2.0 µg/mL of Alexa Fluor 488-conjugated EGF (Life 
Technologies). Cells were then analyzed by fluorescence recovery after photobleaching 
technique (FRAP) (38, 39) under two conditions. In the first approach, which was 
adapted from Sprague et al. who describe the use of FRAP for analysis of binding 
interactions (40); unbound Alexa Fluor 488-conjugated EGF was maintained in the bath, 
which allowed us to measure EGF on/off rate (as shown in Figure 6.2C). In the second 
set of experiments, unbound EGF was removed by washing before imaging, in which 
case membrane fluidity was measured (Figure 6.5A).   Cells were incubated at 37 ˚C for 
the duration of the FRAP experiments. Then, using a Zeiss 780 FCS Confocal 




monitored emissions at 525 nm. The laser intensity was adjusted to obtain a 75 % loss in 
fluorescence in a 3 µm by 1 µm rectangular photobleached region on the apical focal 
plane of the cell membrane; for rapid bleaching high laser intensities were used for a 
single bleaching scan (0.278s). Multiple regions were imaged pre- and post- 
photobleaching using low laser intensities and recovery fluorescence in the selected 
regions was tracked over time.  
The fluorescent intensity measured at each time point (I(t)) was then converted to a 
normalized fluorescent intensity (NFI(t)) normalized using the following equation: 
Normalized Fluorescent Intensity= [{I(t)-I(post bleach)}/I(prebleach)]/I(post recovery) 
The NFI was then plotted against time and fit to a one phase exponential association 
curve using  the GraphPad Prism 6 software (GraphPad Software, Inc.; La Jolla, CA).  
From the fit of the curves, time constants for half recovery were derived (t0.5).  
6.2.7 Mathematical Model of EGFR Trafficking.  
The effect of parameter changes in the western blot and saturation binding experiments 
were analyzed by a macroscopic level model (41) that contained four components: 
synthesis, internalization, degradation, and recycling. The baseline parameters used in 
this study were based on those determined in human mammary epithelial cells by 
Hendricks et al., (41).  We note that these parameters were derived from a different cell 
line and therefore were not necessarily quantitatively predictive in the currently-used 
SW1990 line. However because EGFR trafficking across cell types utilizes the four basic 
components synthesis, internalization, degradation, and recycling) described in this 
model, these modeling experiments were implemented to provide qualitative support for 




     The model consisted of four differential equations with variables: free EGFR (Rs), 
internalized free EGFR (Ri), EGF-EGFR complex on surface (Cs), internalized EGF-
EGFR complex (Ci). These equations account for the binding and release of EGF (L) 
from free EGFR (Rs), which are synthesized at rate Sr, at rates kon and koff, respectively. 
EGF-EGFR complexes on surface (Cs) are then internalized at rate kec, degraded at rate 
kxc, and recycled at fraction fxc.  Free EGFR (Rs) is internalized at rate ker, degraded at 
rate kxr, and recycled at fraction fxr. Internalization, ke, is governed by rates kec and ker.  
Degradation, kx, is governed by rates kxc and kxr, while recycling, fx, is governed by fxc 
and fxr.  
The model was designed to simulate the conditions used in the western blots and EGF 
saturation binding experiments (5), which involved an overall incubation period of 48 h 
(with analog addition simulated through alterations in various rate constants) with serum 
starvation over the last 24 h, and finally 2 min exposure to 10 ng/mL of EGF.  Rate 
constants then were varied incrementally to model the final values of total EGF-EGFR 
complexes (Cs+Ci), total available cell surface EGFR (Rs) and total EGFR 
(Rs+Ri+Cs+Ci). These values were then normalized against baseline values and then 
plotted against changes in rate constants normalized against baseline. The rate constants 
manipulated were kon, koff, and collectively, ke, kx.  
6.2.8 Internalization Assays.  
Cells were incubated for 48 h with 1,3,4-O-Bu3ManNAc with serum starvation over the 
last 24 h.  The cells then were washed with PBS, treated with enzyme free cell 
dissociation buffer (Life Technologies) until they detached from the culture plate, 




coulter counter. Cells were then washed twice in Live Cell Imaging Solution (Life 
Technologies) supplemented with 1.0% bovine serum albumin (BSA) and 20 mM 
glucose and treated with 0.5 µg/mL of filipin (Sigma Aldrich) or 100 mM of lactose 
(Carbosynth) for 60 min. Cells were then incubated at 37°C for 30 min with 2.0 µg/mL of 
Alexa Fluor 488-conjugated EGF (Life Technologies). Cells were washed three times, 
followed by acid washing for 5.0 min with 0.2 M glycine (pH 2.5), washed thrice and 
finally analyzed using flowcytometry with an Accuri C6 Flowcytometer. The cell 
population of interest was gated appropriately and 10
4
 cells falling within the gated area 
were measured and used to determine the mean fluorescence of the cell population; the 
histograms for these experiments are shown in Suppl. Figure S3. 
6.2.9 Lectin Binding Assays.  
Cells were incubated for 48 h with 1,3,4-O-Bu3ManNAc.  The cells were washed with 
PBS, treated with enzyme free cell dissociation buffer (Life Technologies) until they 
detached from the culture plate, collected, and counted and cell numbers were normalized 
using the Beckman Z2 cell coulter counter.  Cells were then washed twice in PBS. Cells 
were then incubated at room temperature for 120 min with 5.0 µg/mL of Flourescein 
labeled RCA lectin (Vector Laboratories).  Cells were washed three times in PBS and 
analyzed using flowcytometry with an Accuri C6 Flow cytometer. The cell population of 
interest was gated appropriately and 10
4
 cells were used to determine mean fluorescence.  
6.2.10 Confocal Microscopy for Endosome Sizing.  
Cells were incubated for 48 h with 1,3,4-O-Bu3ManNAc with serum starvation over the 
last 24 h. Cells were then washed in Live Cell Imaging Solution (Life Technologies) 




then incubated at 37°C for 10 min or 30 min with 2.0 µg/mL of Alexa Fluor 488-
conjugated EGF (Life Technologies). Cells were then fixed, nuclei were stained with 
DAPI and then imaged on Zeiss AxioObserver with 780-Quasar confocal module & FCS. 
Endosome size was determined using ImageJ software. 
6.2.11 Quantitative Reverse Transcription-Polymerase Chain Reaction (qRT-PCR).  
Total RNA was isolated using Trisol
®
 reagents (Gibco BRL) and reversed transcribed 
using the high capacity RNA-to-cDNA kit (Applied Biosystems).  PCR amplifications 
were performed using the following TaqMan® Gene Expression Assays from Applied 
Biosystems: BCL3 (Assay ID: Hs00180403_m1), MYC (Assay ID: Hs00153408_m1), 
VEGFA (Assay ID: Hs00900055_m1), MMP2 (Assay ID: Hs01548727_m1), MMP7 
(Assay ID: Hs01042796_m1) and GAPDH (Assay ID: Hs03929097_g1).  qRT-PCR was 
performed using the Step-One Plus Real-Time PCR system (Applied Biosystems) with 
the thermocycling conditions of 50 ˚C for 2.0 min, 95 ˚C for 10 min followed by 40 
cycles of 95 ˚C for 15 s and 60 ˚C for 1.0 min.  
6.2.12 Statistical Analysis.  
Data was expressed as means ± standard error (SEM). Statistical significance was 
determined using one way ANOVA with a Dunnett’s post-test to compare means of 
different samples with the control or a Bonferroni post test to compare specific pairs of 






6.3.1 Treatment with 1,3,4-O-Bu3ManNAc Increased EGFR Sialylation.  
In a previously-reported “glycosite” glycoproteomic analysis (3), we found with medium 
confidence that 1,3,4-O-Bu3ManNAc increased sialylation by ~2.1 fold at least one N-
glycan site on EGFR (ASN351 of EGFR isoform c, gi41327734)). To confirm that 1,3,4-
O-Bu3ManNAc legitimately increased EGFR sialylation, and to gain a sense of the 
overall change in the levels of the sugar (for context, the previous results only provided 
information on one of the 10-12 putative N-glycan sites found on EGFR) in the current 
experiments we used two additional methods to measure sialylation. In both cases I began 
by immunopurifying EGFR from control and analog-treated cells.  Then, in one set of 
experiments, the purified EGFR was quantified by western blots (Figure 6.1A) and in 
tandem, stained for α2,6 sialic acid using HRP-linked SNA-1 lectin. In an independent 
method, the EGFR was digested with sialidase and the released sialic acid was 
determined by FACE analysis (Figure 6.1B). These experiments showed both an 
increase in overall sialylation level (as measured by FACE) as well as an increase in α2,6 
sialylation (determined by SNA-1 staining). 
6.3.2 Surface Localization of EGFR was Decreased by 1,3,4-O-Bu3ManNAc 
Treatment.  
EGF saturation binding assays from a previous study (5) suggested that surface display of 
EGFR was suppressed by 1,3,4-O-Bu3ManNAc treatment. To gain further evidence for 
this observation, I directly labeled surface EGFR using Alexa Fluor-488-conjugated mAb 




fluorescence at two magnifications (20x, panel A and 43x, panel B) confirmed that 
analog treatment decreased surface localization of EGFR.  
6.3.3 FRAP Assays Indicate Minimal Changes in Receptor-Ligand Binding Affinity. 
Based on reports by others that increased sialylation achieved through genetic 
manipulation diminishes EGFR signaling by inhibiting dimerization of this surface 
receptor (29, 33, 34), I initially expected that increased sialylation achieved through 
1,3,4-O-Bu3ManNAc treatment (e.g., as shown in Figure 6.1), would have a similar 
effect. Western blot assays (following the procedures described by Liu et al., (29), data 
not shown) however, were not able to reproduce the dimerization results in a statistically 
significant manner. Therefore I explored a second method to determine if the reduced 
surface presence of EGFR (Figure 6.2) was a consequence of reduced dimerization by 
using fluorescent recovery after photobleaching (FRAP) assays to evaluate receptor 
(EGFR)-ligand (EGF) binding kinetics, which several papers suggest could be influenced 
by receptor dimerization (42-44).  
In these experiments, a portion of the cell membrane was photobleached while the 
cells were in a bath containing Alexa Fluor 488-conjugated EGF. The rate at which 
bleached EGF molecules were released and unbleached Alexa Fluor 488-conjugated EGF 
from solution bound to the vacated receptors was measured by monitoring the recovery 
of fluorescence. In this approach the t0.5 value, which is inversely proportional to the rate 
at which bleached EGF molecules are released and unbleached Alexa Fluor 488-
conjugated EGF from solution bind to the vacated receptors, provides an indirect 
measurement of receptor-ligand binding. The t0.5 values determined for 1,3,4-O-




respectively, Figure 6.2C) indicating that increased sialylation of EGFR did not directly 
affect EGF binding. Indications that ligand binding is linked to the dimerization status of 
EGFR (42-44) led to the expectation that EGF binding kinetics would have differed 
between 1,3,4-O-Bu3ManNAc-treated and control cells if the dimerization status of 
EGFR had been perturbed by analog treatment. Because this expectation was not met, 
this experiment provided additional evidence that this compound did not primarily alter 
EGFR activity by changing its dimerization status.   
6.3.4 Computational Modeling Supported the Galectin Lattice Mechanism and 
Predicted NCM-mediated Endocytosis.  
The results reported above suggested that 1,3,4-O-Bu3ManNAc-mediated changes to 
sialylation impact EGFR by a different mechanism compared to genetic methods that 
alter dimerization. Accordingly, I considered whether this compound affected EGFR 
trafficking via an alternative glycosylation-based mechanism, which is through changes 
to the galectin lattice (45), as illustrated in Figure 6.3. However before undertaking 
additional experiments to support this hypothesis, we implemented a MATLAB model of 
the surface dynamics and recycling kinetics of this receptor (Figure 6.4A) (41) to gain 
support for the galectin lattice mechanism and also to evaluate whether any competing, 
and perhaps more compelling, hypotheses existed. The modeling simulations were based 
on the equations shown in Figure 6.4B, which covered parameters relevant to 
experimental endpoints described in our previously published work that showed that 
1,3,4-O-Bu3ManNAc treatment led to decreased levels of p-EGFR (Cs+Ci) and no 
significant change in total amount of EGFR (Rs+Ri+Cs+Ci) for a short time period (i.e., 




of surface-localized EGFR (Rs) present on the cells immediately before the addition of 
EGF (e.g., as shown in Figure 6.2).  
The usefulness of the model for deciphering different ways by which 1,3,4-O-
Bu3ManNAc could affect EGFR is illustrated by scenarios illustrated in Figure 6.4, 
panels C through F. For example, altering kon values predicted that this parameter was 
correlated with EGFR phosphorylation without affecting overall protein levels (Figure 
6.4C), which was consistent with our previous data on the impact of 1,3,4-O-
Bu3ManNAc on EGFR (5). The kon rate, however, did not have an impact on cell surface 
levels of EGFR, which was contrary to experimental data (e.g,. as shown in Figure 6.2). 
To address this discrepancy, koff values were varied, leading to the prediction that an 
increase in koff would decrease EGFR phosphorylation with no significant effect on 
overall protein levels (Figure 6.4D).  However, in this case the amount of surface-
displayed EGFR was not altered, which again was inconsistent with our experimental 
findings. Based on an iterative process of this type, we systematically evaluated changes 
to individual internalization rates, recycling rates, and recycling fractions along with 
changes to various combinations of these factors; Supplementary Figure S6.2 shows a 
sampling of various “negative” results where the model predictions did not match one or 
another aspect of our experimental data.  
The modeling results allowed us to discount alternative biochemical mechanisms and 
focus subsequent experimental verification on the galectin lattice, which our early results 
– combined with the modeling – indicated was a plausible biochemical endpoint to 
explain the effects of 1,3,4-O-Bu3ManNAc. In particular, a key simulation that provided 




internalization and recycling rates. In this case, the model predicted that an increase in the 
internalization rate (ke) along with a decrease in the recycling rate (1/kx) would result in 
decreased EGFR phosphorylation accompanied by a very slight increase in overall EGFR 
levels (Figure 6.4E, upper panel). Significantly, this set of variables also predicted the 
lower initial EGFR levels observed on the cell surface after treatment with 1,3,4-O-
Bu3ManNAc (i.e., as shown in Figure 6.2) seen before the simulated addition of EGF 
(Figure 6.4E, lower panel).  
The simulation just mentioned (as shown in Figure 6.4E) indicated that 1,3,4-O-
Bu3ManNAc increased the rate of EGFR internalization, consistent with the galectin 
lattice mechanism outlined in Figure 6.3. In addition, the decreased recycling rate (1/kx) 
predicted in Figure 6.4E was consistent with a shift towards non-clathrin mediated 
(NCM) endocytosis and away from clathrin mediated internalization. In particular, the 
shift away from clathrin mediated internalization was predicted by the simulation in 
Figure 6.4F that shows predicted EGFR behavior for clathin mediated internalization.  
Specifically, a simulated increase in both the internalization rate (ke) and the recycling 
rate (kx) –  as occurs during clathrin mediated internalization – indicated that a rapid 
decrease in total EGFR levels (i.e., within the 2 min time frame covered in the 
simulation) should occur if this mode of EGFR recycling was taking place.  This result, 
however, was not obtained experimentally as we previously showed (5) thereby leading 
us to consider alternative recycling mechanisms such as NCM endocytosis. Together, our 
early experimental results and the modeling supported a mechanism where 1,3,4-O-




coated internalization, internalized moieties are directed for degradation rather than 
recycling (46), leading us to next investigate NCM endocytosis in more detail.  
6.3.5 FRAP Assays Indicate Increased Membrane Fluidity and Support 
Internalization via NCM Endocytosis.  
To evaluate whether increased membrane fluidity contributed to increased internalization 
of EGFR predicted by the model, FRAP assays were conducted in the absence of 
unbound Alexa Fluor 488-conjugated EGF, in which case the rate that fluorescently-
labeled EGF bound to receptors adjacent to the bleached region diffuses into the bleached 
areas can be monitored to provide a measure of membrane fluidity. The t0.5 values 
determined in this experiment, which are inversely proportional to the rate of diffusion 
were noticeably different in the 1,3,4-O-Bu3ManNAc treated cells that had faster 
diffusion rates compared to non-treated controls (control t0.5= 17.77, treated t0.5= 7.112, 
Figure 6.5A). This finding was consistent with the proposed disruption of the galectin 
lattice caused by an increase in sialylation (Figure 6.3).   
As a caveat, in a typical FRAP assay, the curve fit R
2
 values did not achieve a 
sufficient degree of statistical confidence to definitively prove that increased membrane 
diffusion occurred. The observed trends nevertheless were repeatable and offered 
tentative support for the premise that the impact of 1,3,4-O-Bu3ManNAc on cell surface 
dynamics was real. Importantly, the increased fluidity and subsequent changes in 
internalization suggested by the FRAP assays was confirmed in an independent flow 
cytometry assay (Figure 6.5B). Furthermore, this increase was completely ablated by 
filipin (an NCM endocytosis inhibitor) pretreatment (Figure 6.5C), confirming that NCM 




Next, to further implicate the galectin lattice mechanism, pre-treatment with lactose 
(a galectin binding inhibitor) resulted in an increase in the internalization rate of EGFR in 
untreated controls towards levels observed in analog-treated cells (Figure 6.5D) 
indicating that the inhibitory impact of increased sialylation could be mimicked by this 
small molecule as expected if the galectin lattice played a role. Finally, Ricinus 
communus agglutinin (RCA) binding, a lectin that recognizes terminal galactose residues 
(which also are the critical binding epitopes for galectins when present on highly-
branched N-glycans) showed decreased binding in 1,3,4-O-Bu3ManNAc-treated cells 
(Figure 6.5E). The affinity of RCA and galectins for terminal galactose residues is 
regulated in a yin-yang manner by sialylation because sialic acids mask binding sites for 
these lectins (47). The RCA results (both from this study (Figure 6.1) and from our 
previous investigation of this cell line, (3)), therefore, indicated that potential galectin 
binding sites were masked with increasing levels of sialyation; in particular α2,6-linked 
sialic acids strongly increase (i.e., approximately double based on SNA staining, Figure 
6.3C) in 1,3,4-O-Bu3ManNAc-treated SW1990 cells (3, 4).     
6.3.6 Time Course Experiments support NCM Endocytosis.  
The premise that NCM endocytosis played a role in the mechanism of 1,3,4-O-
Bu3ManNAc necessitated as series of experiments conducted at longer time points than 
the two minute evaluation in our previous work and modeling simulations. In particular, 
NCM endocytosis requires 30 to 90 min to direct cell surface elements for degradation 
(46). Accordingly, to confirm that 1,3,4-O-Bu3ManNAc treatment resulted in increased 
NCM endocytosis, two experiments were conducted over longer periods of times than the 




in advance of degradation, there should be evidence of a shift from clathrin-coated 
internalization to NCM endocytosis. To assess these two modes of recycling at 10 and 30 
min time points leading up to the onset of degradation, I measured endosome size based 
on evidence that clathrin-coated endosomes (~100-150 nm) (48-50) are larger than NCM 
endosomes (~50-80 nm) (51, 52) by directly visualizing endocytosis. In these 
experiments, 1,3,4-O-Bu3ManNAc-treated and control cells were incubated with Alexa 
Fluor 488-conjugated EGF for 10 min (Figure 6.6A) or 30 min (Figure 6.6B) at 37⁰C, 
fixed, and then imaged using confocal microscopy. Endosome sizing by Image J showed 
a significant shift in endosome population from larger endosomes toward smaller 
endosomes in the analog-treated cells compared to untreated controls. This shift toward 
smaller endosomes was consistent with increased NCM endocytosis at the expense of 
clathrin-coated endocytosis and provided additional support for the hypothesis that EGFR 
internalization became biased towards NCM endocytosis upon 1,3,4-O-Bu3ManNAc 
treatment. 
Finally, because NCM endosomes are primarily fated for degradation (46), I reasoned 
that EGFR would experience increased degradation at longer EGF exposure times (e.g,. 
at 30 min (Figure 6.7A) or 60 min (Figure 6.7B)) in 1,3,4-O-Bu3ManNAc-treated cells 
compared to  untreated controls. The progressive time-dependent increase in the 
degradation of EGFR provided in these data further supported the hypothesis that 1,3,4-




6.3.7 ERK1/2- and AKT-driven Signaling do not Respond to 1,3,4-O-Bu3ManNAc 
Treatment.  
I next sought to gain additional insight into the consequences of increased internalization, 
and presumably, signaling activity, of EGFR. This receptor must be phosphorylated to 
initiate signaling and we previously showed that changes in p-EGFR levels in 1,3,4-O-
Bu3ManNAc treated SW1990 cells, while modest, were amplified downstream in 
stronger inhibition of STAT3 phosphorylation (p-STAT3) (5). Notably, this decrease, 
which was reproduced in the current experiments (Figure 6.8A) was not accompanied by 
a significant change in overall STAT3 levels (Figure 6.8B), suggesting that the decreased 
levels of p-STAT3 were a consequence of pathway activation and not changes in the 
overall levels of this protein. 
Because p-ERK1/2 and p-AKT are activated by EGFR phosphorylation similar to p-
STAT3, levels of these downstream effectors of EGFR signaling were expected to also be 
reduced concomitant with decreased p-EGFR in 1,3,4-O-Bu3ManNAc-treated cells. 
Accordingly, to test this premise, EGFR-driven signaling via the ERK1/2 and AKT 
pathways was monitored by measuring phosphorylated ERK1/2 (p-ERK1/2) and 
phosphorylated AKT (p-AKT) levels using western blot analysis. These experiments, 
however, showed that no statistically significant change in SW1990 cells occurred (p-
ERK1/2 results are shown in Figure 6.8C and p-AKT results in Figure 6.8D).  
The lack of response for p-ERK1/2 and p-AKT in 1,3,4-O-Bu3ManNAc-treated 
SW1990 cells can be explained by observations that ERK1/2 and AKT signaling can be 
activated via RAS (35, 53); indeed, mutations that constitutively activate RAS signaling 




Relevant to this study, in pancreatic cancer the RAS pathway is constitutively activated in 
the SW1990 cell line (55) as well as in ≥ 81% of pancreatic cancer patients (56, 57). As a 
result, ERK1/2 and AKT signaling can be activated by these alternate pathways thereby 
rendering moot the influence of reduced p-EGFR levels in 1,3,4-O-Bu3ManNAc-treated 
SW1990 cells on these two endpoints. Nevertheless, STAT3 activity, while linked to 
RAS signaling in a parallel and complementary manner (58), generally is not primarily 
driven by RAS (59, 60).   Accordingly, it seemed reasonable that inhibition of STAT3 
could provide therapeutic benefit even in the presence of constitutively active RAS; to 
test this premise I next evaluated the expression of selected STAT3-driven oncogenes in 
1,3,4-O-Bu3ManNAc-treated cells. 
6.3.8 Downstream STAT3-driven Genes Respond to Analog-mediated p-EGFR 
Inhibition.  
Although not all downstream effectors driven by p-EGFR are inhibited by 1,3,4-O-
Bu3ManNAc treatment in SW1990 cells (e.g., ERK1/2 and AKT signaling do not 
respond as just described), I found that several oncogenes activated by p-STAT3 were 
nonetheless successfully inhibited by treatment with this sugar analog. In particular, 
reduced p-STAT3 levels in 1,3,4-O-Bu3ManNAc-treated cells (Figure 6.8A) was 
manifest in decreased expression of the STAT3-driven genes BCL3, MMP2, and MMP7 
(Figure 6.9A). This down-stream modulation of several genes that contribute to cancer 
progression demonstrates that even modest changes in the activity of surface receptors 
due to altered glycosylation has the potential to be therapeutically beneficial.   
Conversely, offsetting events – including the lack of response of ERK1/2 and AKT to 




responsive genes including MYC and VEGFA (61) (Figure 6.9B) – suggest that a 
compound such as 1,3,4-O-Bu3ManNAc is unlikely to comprise a “stand alone” drug for 
advanced stage pancreatic cancers. Indeed, “glycosylation-only” EGFR-targeting 
therapies have recently been judged to be ineffective as cancer therapies (33). Instead, as 
we recently reported, synergy between otherwise marginally effective TKI drugs and our 
approach (5) holds potential for combination therapy. The mechanism behind the 
observed synergy was unclear, however, especially considering that very there are very 
few strategies where drug synergy is achieved by targeting the same biomolecular target 
(e.g., in this case EGFR).  To address this issue, I sought to gain mechanistic insight into 
how two EGFR-targeting strategies that are only marginally effective in SW1990 cells 
when used alone work in concert to facilitate strong synergy.  
6.3.9 Synergy Between 1,3,4-O-Bu3ManNAc and Erlotinib.  
To gain insight into the previously observed synergy between 1,3,4-O-Bu3ManNAc and 
EGFR-targeting TKI drugs such as erlotinib (5), western blotting for various EGFR 
signaling components was performed for SW1990 cells treated with either 1,3,4-O-
Bu3ManNAc or the TKI drug, or both in combination. First, as expected from previous 
experiments, 1,3,4-O-Bu3ManNAc alone did not significantly affect EGFR levels 
(Figure 6.10A). In this experiment, erlotinib treatment did decrease EGFR levels and 
cotreatment with both compounds led to a similar decrease in EGFR indicating a lack of 
synergy in this particular endpoint. Next, EGFR phosphorylation was tested and analog 
treatment (as expected from previous results) as well as erlotinib treatment led to 
decreased levels of p-EGFR but again cotreatment did not synergystically decrease p-




altered either p-AKT or p-ERK1/2 levels (Figure 6.10C and Figure 6.10D respectively), 
again not providing insight into the synergy between 1,3,4-O-Bu3ManNAc and erlotinib.   
Instead, the observed synergy between 1,3,4-O-Bu3ManNAc and erlotinib hinged on 
STAT3 where levels of p-STAT3, although not affected by erlotinib on its own, 
experienced an amplified decrease upon co-treatment with 1,3,4-O-Bu3ManNAc 
compared to treatment with the sugar analog by itself (Figure 6.10E). Of the many 
conditions tested, the observation that co-treatment amplifies the inhibition of p-STAT3 
provides at least a partial explanation for the synergy observed between 1,3,4-O-
Bu3ManNAc and TKI drugs; I emphasize that other factors such as control of STAT3 by 
cytokine, GPC, and toll-like receptors, which is beyond the scope of the current study, 
may also contribute to the synergy.   
 
6.4 DISCUSSION 
This report builds on previous studies  where I characterized glycosylation in 
advanced stage pancreatic cancer SW1990 cells treated with 1,3,4-O-Bu3ManNAc to 
understand how metabolic flux-driven increases in sialic acid contribute to cancer 
progression (3, 4). Our focus on pancreatic cancer was motivated by poor prognoses for 
this disease, which has a five year survival rate of only ~4% (62);  I reasoned that gaining 
a better understanding of glycosylation could be valuable for devising new treatment 
strategies. In previous work, this premise was supported by our discovery that 1,3,4-O-
Bu3ManNAc synergistically sensitized TKI drug-resistant SW1990 cells to EGFR-




In this paper I first sought to provide a mechanistic understanding of how 1,3,4-O-
Bu3ManNAc – and by extension – increased sialylation, dampened EGFR signaling.  
Based on recent reports by others that increased sialylation achieved through genetic 
manipulation diminishes EGFR signaling by inhibiting dimerization of this surface 
receptor (29, 33, 34), I initially expected that increased sialylation brought about through 
1,3,4-O-Bu3ManNAc treatment (e.g., as shown in Figure 6.1) would have a similar 
effect. Experiments following the protocols described by Yen and coauthors (33), data 
not shown) showed a similar trend, but I were not able to unambiguously reproduce the 
dimerization results in a statistically significant manner. By contrast, I clearly showed a 
reduction in cell surface-localized EGFR in 1,3,4-O-Bu3ManNAc-treated cells (Figure 
6.2A/B). Together with data shown in Figure 6.2C where there was no difference in the 
on/off rate of EGF binding to treated or untreated cells, I concluded that the dimerization 
mechanism observed in other cell types (29, 33, 34) did not apply in the SW1990 cells, or 
at best, offered only a partial explanation for the impact of 1,3,4-O-Bu3ManNAc on 
EGFR activity in this cell line. Either way, this disparity provided impetus for us to 
explore additional mechanisms by which sialylation could affect EGFR signaling. 
Based on the data shown in Figures 6.1 and 6.2 of this paper, plus our previous 
demonstration that 1,3,4-O-Bu3ManNAc approximately doubles overall levels of α2,6-
sialic acid in SW1990 cells (and the current evidence that α2,6-sialylation of EGFR is 
also increase, Figure 6.1A), an attractive alternative (but complementary) mechanism to 
the dimerization hypothesis is this compound had an impact on the galectin lattice 
(Figure 6.3). The basis for this idea is that α2,6-sialic acid inhibits galectin affinity (63) 




EGFR trafficking away from surface display towards internalization and thus reduce its 
signaling (45). In this case, contributions from both increased sialylation of EGFR itself 
(which can directly reduce affinity for lattice by reducing galectin crosslinking of this 
receptor with other surface moieties) and indirect effects due to bulk changes to cell 
surface properties (i.e., an increase in overall membrane fluidity) can help explain the 
reduced EGFR localization observed in Figure 6.2 and the reduced downstream signaling 
previously reported (5). 
Although the galectin lattice mechanism provides an attractive hypothesis to explain 
the effects of 1,3,4-O-Bu3ManNAc on EGFR, the impact of glycosylation on a cell is 
manifold and before embarking on detailed experiments to address this mechanism we 
performed mathematical modeling to (i) confirm whether this hypothesis was plausible, 
(ii) gain evidence whether alternative mechanisms were involved, and (iii) gain deeper 
insight into either of these options. As shown in Figure 6.4, and described in detail in the 
Results section, the modeling results (i) were consistent with an increased internalization 
rate, which is a key feature of the galectin lattice mechanism outlined in Figure 6.3 while 
(ii) no other biochemical mechanisms were implicated when cell surface and 
internalization parameters (i.e., kon, koff, ker, and kex) were modeled.  Furthermore, (iii) the 
modeling results provided important hints that EGFR internalization in 1,3,4-O-
Bu3ManNAc-treated SW1990 cells occurred by NCM endocytosis that directs EGFR for 
degradation and more quickly ablates signaling compared to clathrin-coated 
internalization.  
Based on the hints from earlier experiments (e.g., our prior publications (3, 5) and 




6.4), I conducted a series of experiments that supported increased internalization, and 
more over this internalized shifted to NCM endocytosis in the 1,3,4-O-Bu3ManNAc 
treated cells (Figure 6.5). Next, I showed that EGFR-containing endosomes shifted to a 
smaller size profile in the analog-treated cells, again consistent with a shift away from 
clathrin-coated internalization to NCM endocytosis at shorter time points (e.g., 10 and 30 
min) leading to the ultimate endpoint of degradation (Figure 6.6). Finally, I confirmed 
this final down-stream consequence of increased NCM endocytosis, which is enhanced 
degradation of EGFR over longer time periods of 30 to 60 min (Figure 6.7). Together, 
these sets of data provide an alternative and complementary mechanism based on the 
galectin lattice to describe how increased sialylation can alter EGFR trafficking and 
activity, which up to now has been focus more narrowly on EGFR:EGFR dimerization. 
 As the next major thrust of this work, I sought to gain additional insight into reasons 
why EGFR-targeting TKI drugs, despite the important role that this receptor plays in 
pancreatic cancer, have not been used to treat this type of malignancy successfully in the 
clinic (64). This lack of efficacy is evident from observations that many pancreatic cancer 
lines – including SW1990 cells, which were selected for use in this study in large part 
because they possess mutations such as constitutively-activated RAS and are resistant to 
TKI drugs in a way that reflects the majority of clinical cases of pancreatic cancer  – 
require tens of micromolar concentrations of TKI drugs to observe a response (compared 
to corresponding nanomolar concentrations in sensitive cells) (65).   
Finally, because 1,3,4-O-Bu3ManNAc dramatically sensitized drug resistant SW1990 
cells to the TKI drugs erlotinib and gefitinib (5) thereby enhancing the potential 




underpinnings of this finding by focusing on known EGFR-responsive pathways. These 
efforts first provided some insight into why EGFR-targeting drugs are not particularly 
effective for treating pancreatic cancer insofar as an 1,3,4-O-Bu3ManNAc-driven 
reduction in p-EGFR levels did not have an impact on ERK1/2 and AKT signaling in 
SW1990 cells, most likely because these pathways are upregulated by alternate 
mechanisms in pancreatic cancer. I nonetheless showed that the impact of 1,3,4-O-
Bu3ManNAc on STAT3, an important downstream effector pathway of EGFR, is 
sufficient to translate into potential anti-cancer activity through down-regulation of 
oncogenes such as BCL3, MMP2 and MMP7 (Figure 6.9A).  
It is noteworthy that the synergy between 1,3,4-O-Bu3ManNAc and the EGFR-
directed TKI drugs erlotinib and gefitinib was achieved, at least in part, by targeting the 
same receptor. Because synergistic therapeutics typically are directed at completely 
different targets (although exceptions where the same receptor is targeted are known 
(66)), this was an unusual situation that our evidence suggests was facilitated by the 
ability of our approach to change the trafficking pattern of EGFR. To elaborate briefly, as 
far as drug synergy is concerned, erlotinib has no known way to impact the galectin 
lattice and EGFR is expected to be internalized normally via clathrin coated endocytois in 
cells treated with this drug. Therefore, even though this TKI reduces overall cellular 
levels of EGFR phosphorylation, signaling continues when this receptor is internalized. 
As a result, even though overall levels of EGFR decrease when SW1990 cells are treated 
with erlotinib (as shown in Figure 6.10) there is only a negligible impact on downstream 
signaling explaining why there have been reports that this TKI only has a minimal impact 




Based on this explanation, the key contribution of 1,3,4-O-Bu3ManNAc is to shunt 
EGFR internalization towards NCM endocytosis, which rapidly reduces signaling 
activity. As a result the reduced levels of EGFR brought about by erlotinib – although 
relatively minor – combine with the sugar analog’s ability to shunt this molecule down a 
non-active internalization mechanism (i.e., NCM endocytosis) – and together result in a 
synergistic reduction in down-stream EGFR signaling that is much greater than that 
realized by either 1,3,4-O-Bu3ManNAc or the TKI drugs on their own. Numerous studies 
have shown that EGFR signaling can continue from within endosomes (67, 68). In fact, 
even in the absence of surface signaling cues, clathrin-coated endosomal signaling can 
activate signaling pathways and be adequate to promote cell survival (69); moreover, 
clathrin-mediated endocytosis is essential for MAPK activation (70) and is responsible 
for the activation and cytoplasmic transport of STAT3 to the nucleus (71).  
These observations offer an explanation for how erlotinib-treated SW1990 cells can 
maintain STAT3 activity despite lower overall levels of EGFR and p-EGFR. Instead, for 
the reduced levels of EGFR caused by erlotinib to be manifest at the whole cell level, co-
treatment with 1,3,4-O-Bu3ManNAc is needed to shift clathrin-mediated internalization 
towards NCM endocytosis. From a practical perspective, this synergy holds intriguing 
potential to combat drug-resistant pancreatic cancer, which remains virtually untreatable 
to date. 
As concluding remarks, this paper provides evidence for a new way that flux-driven 
sialylation can impact EGFR signaling (e.g., through masking of galectin binding 
epitopes (72) rather than intervening in the production of these structures (73-75)) with 




trafficking towards NCM endocytosis. However, due to the complexities of both 
glycosylation and cell signaling, I emphasize several caveats. First, while I did not obtain 
evidence to support a role of flux-driven sialylation in affecting the dimerization status of 
EGFR in SW1990 cells, my experiments also did not conclusively rule out this 
mechanism. Moreover, evidence exists that there is a third mechanism through which 
increased sialylation could suppress EGFR signaling by increasing cellular levels of 
ganglioside GM3 (76); this possibility was not addressed in the current study.  In a 
second direction, another caveat is that by altering the galectin lattice and by extension 
the bulk fluidic properties of the plasma membrane, numerous additional pathways 
beyond EGFR signaling could be affected (74, 75, 77). Therefore, although I present 
strong evidence that 1,3,4-O-Bu3ManNAc acts on EGFR through galectin lattice effects, 
the impact on cell-level behavior (e.g., synergy with TKI drugs) likely has additional 
inputs beyond the scope of this study. Finally, the complexities of cell signaling and 
glycosylation raise the cautionary note that the current results from SW1990 cells may 
not be widely applicable to any cell type, although I do note that the application of the 
computational EGFR trafficking model, which was previously optimized for human 
mammary epithelial cells (41), proved to provide valuable qualitative information that 
guided the study of this pancreatic cancer line. 
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Figure 6.1: Sialylation of immunopurified (IP’d) EGFR from SW1990 cells.  The cells were treated with 
100 μM (or 0 µM for controls) of 1,3,4-O-Bu3ManNAc and EGFR was IP’d from each condition.  (A) One 
aliquot of the IP’d EGFR was separated using PAGE and the resulting blots were probed with an EGFR-
recognizing antibody or HRP-linked SNA-1 lectin; the SNA-1 staining was ablated by the binding 
competitor lactose.  When the data from the western blot was quantified and normalized to EGFR levels, 
the bar graph verifies that there was an increase in α2,6 sialylation of EGFR in the 1,3,4-O-Bu3ManNAc-
treated cells. (B) A second aliquot of IP’d EGFR was digested with sialidase, which was analyzed by 
Fluorescent Assisted Carbohydrate Electrophoresis (FACE). Quantification of the FACE bands 
(normalized to EGFR levels determined from the western blots) provided independent verification that 
overall sialylation of EGFR increased with 1,3,4-O-Bu3ManNAc treatment Each experiment includes at 
least three biological replicates and the bands were quantified using Image J with data expressed as mean 
± standard error mean (SEM). * indicates a p value of < 0.05. 
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Figure 6.2: Confocal imaging of EGFR in SW1990 cells treated with 1,3,4-O-Bu3ManNAc.  The treated 
cells, in comparison with untreated controls, were imaged at (A) 20X and at (B) 43X magnifications after 
being fixed and stained with Alexa Fluor-488 conjugated EGFR mAb (green) and DAPI (blue). 
Quantification of mAb staining, normalized to DAPI, showed a decrease in surface localized EGFR when 
SW1990 cells were treated with 100 µM of 1,3,4-O-Bu3ManNAc as shown in the bar graphs. Each 
experiment includes at least three biological replicates and the fluorescent intensity of both Alexa Fluor-
488 and DAPI were quantified using Image J with data expressed as mean ± standard error mean (SEM). * 
indicates a p value of < 0.05. Scale bars represent 100 µm and 50 µm respectively (C) A representative 
fluorescent recovery after photobleaching (FRAP) assay is shown, in which recovery rates are inversely 
proportional to t0.5 when Alexafluor 488-conjugated EGF is present in the bath, indicated that receptor 
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Figure 6.3: Proposed galectin lattice-mediated mechanism for modulation of EGFR signaling through 
1,3,4-O-Bu3ManNAc treatment. The combined modeling and early experimental results were consistent 
with the depicted biochemical mechanism where destabilization of the galectin lattice occurs due to the 
masking of galectin-binding epitopes by analog-driven increased sialylation of N-linked glycans.  (A) 
Cancer cells often have highly organized, less-mobile surface receptors (e.g., the green structure 
represents EGFR while the black structures represent any other cell surface glycoprotein) in part because 
of a highly formed galectin lattice.  (B) One result of a strong galectin lattice is lengthened residence times 
for EGFR on the cell surface (45), resulting in enhanced phosphorylation that lead to increased 
downstream EGFR signaling, which contributes to cancer progression. (C) 1,3,4-O-Bu3ManNAc treatment 
leads to an increase in sialylation of N-linked glycans bound to EGFR, based on lectin-staining data 
(specifically SNA binding as shown in the representative FACS plot depicts globally increased expression 
of α2,6-linked sialic upon 1,3,4-O-Bu3ManNAc treatment, which is consistent with both the data shown in 
Figure 1 and our previous results (3)); glycans terminated with α2,6-linked sialic acids mask galactose 
residues and negatively regulate galectin binding (63).  (D) In turn, reduced galectin binding decreases 
lattice strength, thereby increasing the surface mobility of EGFR and enhancing its removal from the cell 
surface (45). (E) Ultimately – over time periods longer (e.g., 30 to 90 min) than the 2 min time frame 
investigated in our previous work (5) – this increased rate of internalization predicts faster inactivation of 
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Figure 6.4: Mathematical model of EGFR trafficking.  (A) The general schematic (adapted from (41), 
with additional details provided in the main text) for modeling EGFR trafficking is shown, with the 
equations used for model output predictions given in (B). In all cases, the simulated data shown represents 
predictions for 48 h of treatment with 1,3,4-O-Bu3ManNAc at which time “initial” baseline levels of cell 
surface EGFR were given (as shown in each lower panel) followed by the simulated 2.0 min exposure to 
EGF (as shown in each upper panel). In each case, the predicted levels of total EGFR are shown in solid 
black and phosphorylated EGFR are shown in hollow circles in the upper graph, while predicted changes 
in surface expression of EGFR are depicted on the lower graph. Panels (C), (D), (E), and (F) show 
simulated results for changes in kon, koff and a combination of ke and kx, respectively.  In (C) and (D) kon and 
koff are respectively increased from left to right whereas in (E) ke was increased, while kx was decreased 
from left to right (which is indicated by “1/kx” on the plots) and in (F), both ke and kx were increased from 
left to right. 
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Figure 6.5: EGFR internalization assays.   (A) FRAP assays, conducted in the absence of excess 
fluorescently-labeled EGF, indicated that the recovery rate (t0.5) was over twice as fast in cells treated with 
1,3,4-O-Bu3ManNAc indicated greater membrane fluidity consistent with decreased galectin lattice 
strength (as outlined in Figure 6.3). (B) Internalization assays conducted in the presence of fluorescently-
labeled EGF for 30 min at 37 C showed that 1,3,4-O-Bu3ManNAc treatment led to a significant increase in 
EGF, and by extension EGFR, internalization. (C) Internalization measured after filipin pretreatment, 
however, was not significantly different between the control and treated samples. (D) Lactose pretreatment, 
a competitive inhibitor of galectin binding, led to an increase in internalization in control cells comparable 
to the increase caused by 1,3,4-O-Bu3ManNAc. (E) RCA lectin binding decreased significantly on 
treatment with 1,3,4-O-Bu3ManNAc. At least three biological replicates were carried out for each 
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Figure 6.6: Confocal imaging of SW1990 cells after (A) 10 min and (B) 30 min of exposure to 2 µg/ml 
Alexafluor 488-conjugated EGF at 37⁰C showed a significantly greater density of larger endosomes in 
non-treated controls compared to cells treated with 1,3,4-O-Bu3ManNAc. The endosomes were sized using 






Figure 6.7: EGFR degradation is enhanced by 1,3,4-O-Bu3ManNAc. Western blot analysis of SW1990 
cells exposed to 10 ng/ml of EGF for (A) 30 min or (B) 60 min after incubation with (or without) 1,3,4-O-
Bu3ManNAc revealed that longer exposures to EGF led to decreased EGFR levels for the treated cells. At 
least 3 biological replicates were carried out for each experiment with data expressed as mean ± standard 






Figure 6.8: Downstrean signaling impact of 1,3,4-O-Bu3ManNAc on STAT and ERK1/2. Western blots 
of lysates from SW1990 cells treated with 1,3,4-O-Bu3ManNAc. The treated (and control) cells were 
subsequently exposed to 10 ng/mL of EGF for 2.0 min and (A) the amount of phosphorylated STAT3 
significantly decreased (B) without a corresponding decrease in STAT3 levels (B).  At the same time, 
phosphorylation of ERK1/2 (C) and AKT (D) were not affected. Each experiment includes at least three 
biological replicates and the blots were quantified using Image J with data expressed as mean ± standard 
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Figure 6.9: RT-PCR analysis of SW1990 cells treated with and without 100 μM of 1,3,4-O-Bu3ManNAc 
showed (A) a significant decrease in expression of STAT3 associated genes BCL3, MMP2 and MMP7 
whereas (B) VEGFA and MYC, which can also be regulated by STAT3, showed increased expression 
(VEGFA) or was not affected (MYC). At least 3 biological replicates were carried out for each experiment 












Figure 6.10: Western blot analysis of SW1990 cells treated with 50 µM 1,3,4-O-Bu3ManNAc, 30 nM of 
erlotinib, or both compounds in combination showed (A) EGFR levels that are not affected by the analog 
alone are decreased by erlotinib. (B) EGFR phosphorylation is inhibited by both compounds individually 
as well as in combination. (C) and (D) p-AKT and p-ERK1/2 levels, respectively, are not significantly 
affected by any of the treatment conditions. (E) p-STAT3 levels are inhibited by the analog but are not 
affected by erlotinib; however the combination of the two compounds leads to significantly lower p-STAT3 
levels when compared to the analog alone. At least 3 biological replicates were carried out for each 
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Supplemental Figure S6.1: Changes in intracellular and surface sialic acid in 1,3,4-O-Bu3ManNAc-
treated SW1990 cells (adapted from Almaraz et al. (2)).  (A) Total (which includes all forms of sialic acid 
found within a cell, black bars) and “glycoconjugate-bound” (which also includes soluble CMP-sialic 
acid, white bars) sialic acid was measured by using the periodate resorcinol assay in cells incubated with 
the indicated concentrations of 1,3,4-O-Bu3ManNAc for 2 days. Cells treated with 100 μM 1,3,4-O-
Bu3ManNAc for 2 days were analyzed by lectin binding with results summarized in (B) and  representative 
flow cytometry data shown in (C) for ricin agglutinin (RCA), (D) Sambucus nigra agglutinin (SNA), and 
(E) Macckia amurensis agglutinin (MAA)  flow cytometry. The error bars represent the S.D. of three 
different experiments.   
This data supports the galectin lattice mechanism described in the main manuscript insofar as SNA binding 
represents levels of α2,6-linked sialic acids, which inhibit access to the underlying galactose/GalNAc 
residues bound by galectins and – as shown above – RCA.  Of note, these global changes to sialylation are 
larger in magnitude than those observed for immunopurified EGFR, which was newly analyzed in the 
current study (with data provided in Figure 6.1 of the main manuscript).  
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Supplemental Figure S6.2:  This figure shows an increased set of mathematical simulations (compared to 
those shown in Figure 3 of the parent publication) that were conducted to ascertain if there were additional 
plausible mechanisms to account for the decreased levels of surface EGFR and cellular p-EGFR observed 
in 1,3,4-O-Bu3ManNAc-treated SW1990 cells.   
Model output predictions, for changes in (A) ker, (B) kec,(C) kxr, (D) kxc, (E) fxr, (F) fxc, (G) a combination of 
fxr and, fxc, and (H) a combination of ke and kx . In each case, predictions for changes in total EGFR are 
shown in solid black and phosphorylated EGFR are shown in hollow circles in the upper graph, while 
predicted changes in surface expression of EGFR are depicted in black on the lower graph.  In each case 
the parameters increase from left to right. 
(A) Modeling of changes in internalization rate of available surface EGFR was not consistent with 
experimental data because while this endpoint did predict that an increase in internalization rate would 
lead to a decrease in EGFR phosphorylation and a decrease in surface bound EGFR, it also predicted that 
a similar decrease in overall EGFR levels would occur, which was not observed in the experimental data. 
(B) Modeling of changes in internalization rate of EGF-EGFR complexes was not consistent with 
experimental data because it does not predict significant changes from the baseline conditions. 
(C) Modeling of changes in recycling rate of unbound EGFR within endosomes was not consistent with 
experimental data because, while it did predict that an increase in recycling rate would lead to a decrease 
in available EGFR on the cell surface, it did not predict the decrease in EGFR phosphorylation that was 
previously observed. 
(D) Modeling of changes in recycling rate of EGF-EGFR complexes within endosomes was not consistent 
with experimental data because it did not predict significant changes from the baseline conditions. 
(E) Modeling of changes in recycling fraction of unbound EGFR within endosomes was not consistent with 
experimental data because while this endpoint did predict that a decrease in the recycling fraction would 
result in a decrease in EGFR phosphorylation and available surface bound EGFR (as observed) it also 




 (F) Modeling of changes in recycling fraction of EGF-EGFR complexes within endosomes was not 
consistent with experimental data because no significant changes from the baseline conditions were 
predicted.  
(G) Modeling of changes in recycling fractions of both unbound EGFR and EGF-EGFR a complexes within 
endosomes was not consistent with experimental data because while it did predict that a decrease in the 
both recycling fractions would result in a decrease in EGFR phosphorylation and available surface bound 
EGFR, it also predicted a similar decrease in overall EGFR levels that was not observed experimentally. 
(H) Modeling of changes in internalization and recycling rates of both available and bound EGFR was not 
consistent with experimental data because while it did predict that an increase in both the internalization 
and recycling rates would lead to an decrease in EGFR phosphorylation and a decrease in surface bound 










Supplemental Figure S6.3: EGFR internalization assays. Internalization assays both (A) before and (B) 
after acid wash showed that 1,3,4-O-Bu3ManNAc treatment (100 µM) leads to a significant increase in 
EGF internalization.  (C) Internalization measured after filipin pretreatment, however, was not 
significantly different between the control and treated samples. (D) Lactose pretreatment led to an increase 
in internalization in control cells comparable to the increase caused by 1,3,4-O-Bu3ManNAc. (E) RCA 
lectin binding decreased significantly on treatment with 1,3,4-O-Bu3ManNAc. At least 3 biological 
replicates were carried out for each experiment with data expressed as mean ± standard error mean 
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